Conditions: Diabetes Mellitus, Type 2
Keywords: DM
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 125
Healthy volunteers: no

Brief summary:
To evaluate the effect of dapagliflozin on body composition in Korean T2DM subjects.12-month, randomised, open-label, parallel-group, multi-centre phase IV study.

Detailed description:
This is a 52 weeks, randomized, open-label, parallel-group, multi-centres phase IV study.

Participants will be randomized 1:1 to receive dapagliflozin 10 mg qd or glimepiride 1\~2 mgqd in an open-label manner for 12 months as add-on to metformin 1000 mg.

Parallel group study design was chosen. In order maintain the practicality of the phase IV study, open label design of study drug delivery was chosen. The reading of the DXA scans will be conducted by one expert in blinded manner. Glimepiride is the most frequently used SUs in Korea and therefore this was chosen as comparator.Dapagliflozin treatment will be associated with reduction of total body FM, BW, abdominal VAT and SAT volume compared with glimepiride.

Arms:
arm 1: Dapagliflozin 10mg + Metformin 1000mg arm 2: Glimepiriide 1-2mg + Metformin 1000mg

Interventions: intervention 1: Dapagliflozin intervention 2: Glimepiride
Intervention descriptions: intervention 1: Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment intervention 2: Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment

Protocol document:
Prot_001.pdf: 
Clinical Study Protocol 
Drug Substance
Dapagliflozin
Study Code
D1690L00067
Version
3
Date
07 June 2016
Effects of Dapagliflozin Compared with Glimepiride on Body Composition 
in Patients with Type 2 Diabetes Inadequately Controlled with Metformin
Sponsor:
AstraZeneca, 17th Luther Building, 42, Olympic-ro 35da-gil, Songpa-gu, Seoul, Korea (138-240)


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
2 (57)
VERSION HISTORY
Version 3.0, 07 June 2016
Protocol Synopsis (National Co-ordinating Investigator, NCI): The national co-ordinating 
investigator was changed and the name, address, e-mail were updated to reflect the new 
NCI. 
Protocol Synopsis (No. of study sites and timeline): the number of study sites was increased 
from 15 to 17, and the estimated date of last subject completed was updated in accordance 
with the current recruitment status.
List of Abbreviations and Definition of Terms: a few abbreviations were added. 
Section 2.2 (Secondary objectives): A secondary objective was added to evaluation the 
effect on lean volume of dapagliflozin compared to glimepiride in subjects with type 2 
subjects. Accordingly, changes in lean mass from baseline using Dual Energy X-ray 
Absorptiometry (DXA) scan (baseline, 52 weeks) was added as the outcome measure for 
the additional objective. 
Section 3.1 (Inclusion criteria): The HbA1c range for the inclusion in the study was 
modified to reflect the HbA1c range found in patients with type 2 diabetes and insufficient
glycemic control in the real-world clinical setting. 
Section 3.2 (Exclusion criteria): Patients with any kind of surgery using foreign metallic 
materials was added as an exclusion criterion to facilitate accurate readings of DXA scan 
results.
Section 3.3 (Subject enrolment and randomization): The word ‘approximately’ was added 
as it refers to an estimated number of enrolled patients. 
Section 4 (Study plan and timing of procedures): The word ‘CT’ was added for 
clarification; and the HbA1C range was modified to reflect the latest change in the inclusion 
criteria of the study. 
Section 5.1.1 (Efficacy assessments – DXA): Evaluation of lean mass was added as it was 
added as a secondary objective. 
Section 5.1.2 (CT): The number and location of slices required for analysis was changed for 
improved CT analysis. 
Section 5.1.5 (Pulse and Blood Pressure): Changes were made to allow the pulse, blood 
pressure, and blood sample collection to be performed in any order.
Section 5.2.3 (Hypoglycemic event): The error in cross-reference was corrected. 


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
3 (57)
Section 6.3.3 (Variable): The error in cross-reference was corrected. 
Section 6.9 (Investigational product and other treatments): This section was moved to a 
separate level-1 heading, Section 7.0 and thereafter. 
Section 7.7.1 (Prohibited medication): The error in cross-reference was corrected.
Section 7.5.2 (Analysis of the secondary variable): The analysis method for the additional 
secondary variable, ‘changes in lean mass from baseline using DXA from baseline to 52 
weeks,’ was added. 
Version 2.0, 2nd November 2015
Section (Protocol Synopsis - Timeline): The timeline was modified to reflect more realistic 
timeline. 
Section (Protocol Synopsis – Objectives): 75g-OGTT related endpoint was deleted, and the 
secondary endpoints in the secondary objective no. 4 was moved to the secondary objective 
no. 1.
Figure 1. Study Flow-chart: The study flow chart was modified to reflect the changed allowed 
dose range of Metformin prior to randomization. 
Section 3.1 (Inclusion criteria): Metformin dose range to be eligible for participation in the 
study was modified to reflect the practical dose of Metformin which patients with type 2 
diabetes who is controlled inadequately with Metformin monotherapy take in real clinical 
practice; and specific descriptions to clarify eligibility criteria for Women of Childbearing 
potential (WOCBP).
Section 3.2 (Exclusion criteria): Breast-feeding patients as an exclusion criterion and 
statements that unstable body weight will be judged by investigator, and alcohol and drug 
abuse will be judged by physician, were added; Exclusion criteria were made more specific 
for clarification. 
Table 1. Study Flow-Chart: Visit window for screening visit was changed to 7 days based on 
routine practice. Urinalysis was added to be performed on every visit. Candidates for 
pregnancy test was specified. The DPP-4 inhibitor as a rescue medication was specified as 
sitagliptin. 
Section 5.1.2 (CT):  The CT imaging method was modified to improve the reproducibility and 
reliability of CT scan results. 
Section 9.2 Subject Data Protection: Detailed description was added for clarification.
Section 9.4 Informed Consent: Detailed description regarding the environment in which the 


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
4 (57)
consent should be obtained was added. 
Version 1.0, 31st June 2015
Initial creation


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
5 (57)
This submission document contains confidential commercial information, disclosure of which 
is prohibited without providing advance notice to AstraZeneca and opportunity to object.
This Clinical Study Protocol has been subject to a peer review according to AstraZeneca 
Standard procedures.  The clinical study protocol is publicly registered and the results are 
disclosed and/or published according to the AstraZeneca Global Policy on Bioethics and in 
compliance with prevailing laws and regulations.


6 (57)
PROTOCOL SYNOPSIS
Effects of Dapagliflozin Compared with Glimepiride on Body Composition 
in Patients with Type 2 Diabetes Inadequately Controlled with Metformin
National Co-ordinating Investigator
Name
Kwan Woo Lee, MD, PhD
Title
Professor 
Address
Department of Endocrinology and Metabolism, Ajou University School of 
Medicine, San 5
Wonchon-dong, Yeongtong-gu,
Suwon, Republic of Korea
443-721
Email
Study site(s) and number of subjects planned
No. of total randomized subjects
120
No. of total enrolled subjects approximately 160
No. of study sites
17  
Study period
Phase of development
Estimated date of first subject enrolled
4Q 2015
IV
Estimated date of last subject completed
4Q 2017
Study design
12-months, randomized, open-label, parallel-group, multi-centres phase IV study
Objectives
Primary Objective:
Outcome Measure:
To evaluate the effect of dapagliflozin on 
body composition in Korean T2DM 
subjects.
Changes in total body fat mass from baseline 
using Dual Energy X-ray Absorptiometry 
(DXA)  scan in 52 weeks after the start of the 
treatment
5HGDFWHG


Clinical Study Protocol Synopsis
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
7 (57)
Secondary Objective:
Outcome Measure :
Evaluate the efficacy in improving 
glycaemic control of dapagliflozin 
compared to glimepiride in subjects with 
type 2 diabetes.
The change in HbA1c levels from baseline to 
52 weeks (baseline, 12, 24, 36 and 52 weeks)
The proportion of Subjects achieving a 
glycemic response, defined as HbA1c <7.0% at 
Week 52
The change in FBS levels from baseline to 52 
weeks (baseline, 4, 12, 24, 36 and 52 weeks)
Evaluate the effect on body weight of 
dapagliflozin compared to glimepiride in 
subjects with type 2 diabetes.
Changes in body weight, waist circumference, 
BMI from baseline (baseline, 4, 12, 24, 36 and 
52 weeks)
Evaluate the effect on blood pressure of 
dapagliflozin compared to glimepiride in 
subjects with type 2 diabetes.
Changes in SBP and DBP from baseline 
(baseline, 4, 12, 24, 36 and 52 weeks)
Evaluate the effect on adipose tissue and 
lean volume of dapagliflozin compared to 
glimepiride in subjects with type 2 
diabetes.
Changes in abdominal VAT and SAT volume, 
VAT/SAT ratio using abdominal CT from 
baseline (baseline, 52 weeks)
Changes in lean mass from baseline using Dual 
Energy X-ray Absorptiometry (DXA)  scan 
(baseline, 52 weeks)
Evaluate the effect on insulin resistance 
of dapagliflozin compared to glimepiride 
in subjects with type 2 diabetes.
Changes in high-sensitivity CRP (hsCRP) and 
adiponectin from baseline (baseline, 52 weeks)
Safety Objective:
Outcome Measure :
Evaluate the safety of dapagliflozin and 
glimepiride
Changes in CBC, electrolytes, lipid, urinalysis 
from baseline (baseline, 4, 12, 24, 36 and 52 
weeks)
Number, frequency and proportion of Subjects 
exposed to adverse events
Number, frequency and proportion of Subjects 
exposed to hypoglycemic events
Target subject population
The study population of this study consists of patients with type 2 diabetes who are 19 - 75 yrs 
old male or female with HbA1c O7.0 and <10.0% in recent 4 weeks. 
Altogether 120 patients in 17 study sites will be randomized to this study.


Clinical Study Protocol Synopsis
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
8 (57)
Duration of treatment
Investigational product, dosage and mode of administration
Investigational Product 
Dapagliflozin tablets, 10 mg, administered orally, once daily as add-on to metformin 1000 mg. 
Comparator
Glimepiride tablets, 1 mg, administered orally 1 or 2 tablets (1mg or 2mg) as add-on to 
metformin 1000 mg will be used at a dose of 1 to 2 mg/day with the up-titration. Glimepiride 
dose can be down-titrated at any time to prevent hypoglycemia.
Statistical methods
The full analysis set will included all randomized subjects who receive at least one dose of 
study medication during the 52 weeks treatment period who have a non-missing baseline 
value and at least one post-baseline value for primary efficacy variable. Baseline demographic 
data will be presented in a descriptive manner. Primary endpoint, change in total body fat 
mass in each treatment arm, will be analyzed with an analysis of covariance (ANCOVA)
model. As for the other endpoints, mixed model repeated measures (MMRM) or ANCOVA 
will be used for continuous variables or logistic regression for binary variable. If any outcome 
variables are inappropriately distributed, non-parametric methods will be used accordingly. 
The statistical significance levels for secondary endpoints will not be adjusted for multiple 
hypothesis testing and will be interpreted only descriptively.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
9 (57)
TABLE OF CONTENTS
PAGE
TITLE PAGE...........................................................................................................1
VERSION HISTORY..............................................................................................2
PROTOCOL SYNOPSIS.........................................................................................6
TABLE OF CONTENTS.........................................................................................9
1.
INTRODUCTION .................................................................................................15
1.1
Background and rationale for conducting this study .............................................15
1.2
Rationale for study design, doses and control groups............................................15
1.3
Benefit/risk and ethical assessment........................................................................15
1.4
Study Design..........................................................................................................16
2.
STUDY OBJECTIVES..........................................................................................17
2.1
Primary objective...................................................................................................17
2.2
Secondary objectives .............................................................................................17
2.3
Safety objectives ....................................................................................................18
2.4
Exploratory objectives ...........................................................................................18
3.
SUBJECT SELECTION, ENROLMENT, RANDOMISATION, 
RESTRICTIONS, DISCONTINUATION AND WITHDRAWAL......................18
3.1
Inclusion criteria ....................................................................................................18
3.2
Exclusion criteria ...................................................................................................19
3.3
Subject enrolment and randomization ...................................................................20
3.4
Procedures for handling incorrectly enrolled or randomized subjects...................20
3.5
Methods for assigning treatment groups................................................................21
3.6
Methods for ensuring blinding...............................................................................21
3.7
Methods for unblinding..........................................................................................21
3.8
Restrictions ............................................................................................................21
3.9
Discontinuation of investigational product............................................................21
3.9.1
Procedures for discontinuation of a subject from investigational product ............22
3.10
Criteria for withdrawal...........................................................................................22
3.10.1
Screen failures........................................................................................................22
3.10.2
Withdrawal of the informed consent......................................................................22
3.11
Discontinuation of the study ..................................................................................23


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
10 (57)
4.
STUDY PLAN AND TIMING OF PROCEDURES.............................................23
4.1
Screening: VISIT 1 ................................................................................................28
4.2
Randomization: VISIT 2........................................................................................28
4.3
Treatment Period: VISITS 3, 4, 5, 6 ......................................................................29
4.4
End of Treatment: VISIT 7....................................................................................30
4.5
Lack of Glycaemic Control, Rescue Therapy........................................................30
5.
STUDY ASSESSMENTS .....................................................................................31
5.1
Efficacy assessments..............................................................................................32
5.1.1
Dual Energy X-Ray Absorptiometry (DXA).........................................................32
5.1.2
CT ..........................................................................................................................32
5.1.3
Height, Weight and Waist Circumference.............................................................32
5.1.4
BMI........................................................................................................................33
5.1.5
Pulse and Blood Pressure.......................................................................................33
5.1.6
Physical Examination.............................................................................................33
5.1.7
Laboratory Efficacy Assessments..........................................................................33
5.1.7.1
HbA1C ...................................................................................................................33
5.1.7.2
Fasting Blood Glucose (FBG) ...............................................................................33
5.1.7.3
hsCRP and Adiponectin.........................................................................................33
5.2
Safety assessments.................................................................................................33
5.2.1
Laboratory safety assessments...............................................................................33
5.2.2
12-Lead ECG .........................................................................................................34
5.2.3
Hypoglycemic Event..............................................................................................34
5.3
Pharmacokinetics ...................................................................................................35
5.4
Pharmacodynamics ................................................................................................35
5.5
Pharmacogenetics ..................................................................................................35
5.6
Biomarker analysis.................................................................................................35
6.
SAFETY REPORTING AND MEDICAL MANAGEMENT ..............................36
6.1
Definition of adverse events ..................................................................................36
6.2
Definitions of serious adverse event......................................................................36
6.3
Recording of adverse events ..................................................................................36
6.3.1
Time period for collection of adverse events.........................................................36
6.3.2
Follow-up of unresolved adverse events................................................................37
6.3.3
Variables ................................................................................................................37
6.3.4
Causality collection................................................................................................38
6.3.5
Adverse events based on signs and symptoms.......................................................38
6.3.6
Adverse events based on examinations and tests...................................................39
6.4
Reporting of serious adverse events.......................................................................39
6.5
Overdose ................................................................................................................39


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
11 (57)
6.6
Pregnancy...............................................................................................................40
6.6.1
Maternal exposure..................................................................................................40
6.6.2
Paternal exposure...................................................................................................40
6.7
Management of IP related toxicities ......................................................................41
6.8
Study governance and oversight ............................................................................41
7.
INVESTIGATIONAL PRODUCT AND OTHER TREATMENTS ....................41
7.1
Identity of investigational product(s).....................................................................41
7.2
Dose and treatment regimens.................................................................................41
7.3
Labelling ................................................................................................................42
7.4
Storage ...................................................................................................................42
7.5
Compliance ............................................................................................................42
7.6
Accountability........................................................................................................42
7.7
Concomitant and other treatments .........................................................................43
7.7.1
General Medication................................................................................................43
7.7.2
Prohibited Medication............................................................................................43
7.8
Post Study Access to Study Treatment ..................................................................44
8.
STATISTICAL ANALYSES BY ASTRAZENECA............................................44
8.1
Statistical considerations........................................................................................44
8.2
Sample size estimate..............................................................................................44
8.3
Definitions of analysis sets ....................................................................................45
8.3.1
Efficacy analysis set...............................................................................................45
8.3.2
Safety analysis set..................................................................................................45
8.3.3
PK analysis set .......................................................................................................45
8.3.4
PRO analysis set ....................................................................................................46
8.4
Outcome measures for analyses.............................................................................46
8.5
Methods for statistical analyses .............................................................................46
8.5.1
Analysis of the primary variable (s).......................................................................46
8.5.2
Analysis of the secondary variable(s)....................................................................47
8.5.3
Subgroup analysis ..................................................................................................48
8.5.4
Interim analysis......................................................................................................48
8.5.5
Sensitivity analysis.................................................................................................48
8.5.6
Exploratory analysis...............................................................................................48
9.
STUDY AND DATA MANAGEMENT BY ASTRAZENECA ..........................49
9.1
Training of study site personnel.............................................................................49
9.2
Monitoring of the study .........................................................................................49
9.2.1
Source data.............................................................................................................49
9.2.2
Study agreements...................................................................................................50


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
12 (57)
9.2.3
Archiving of study documents...............................................................................50
9.3
Study timetable and end of study...........................................................................50
9.4
Data management by delegate of AstraZeneca......................................................50
10.
ETHICAL AND REGULATORY REQUIREMENTS.........................................51
10.1
Ethical conduct of the study...................................................................................51
10.2
Subject data protection...........................................................................................51
10.3
Ethics and regulatory review..................................................................................51
10.4
Informed consent ...................................................................................................52
10.5
Changes to the protocol and informed consent form.............................................53
11.
LIST OF REFERENCES.......................................................................................54
LIST OF TABLES
Table 1
Study Plan detailing the procedures .........................................................25
Table 2
Laboratory Safety Variables.....................................................................34
Table 3
Investigational Products ...........................................................................41
Table 4
Additional Drug........................................................................................41
Table 5
Sample Size Estimate ...............................................................................45
LIST OF FIGURES
Figure 1
Study Flow Chart......................................................................................17
LIST OF APPENDICES
Appendix A
Additional Safety Information..................................................................56


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
13 (57)
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS
The following abbreviations and special terms are used in this study Clinical Study Protocol.
Abbreviation or 
special term
Explanation
A1C
Glycated hemoglobin
AE
Adverse Event 
ALT
Alanine Aminotransferase 
AST
Aspartate Aminotransferase 
BMI
Body Mass Index
BMS
Bristol-Myers Squibb
BP
Blood Pressure
CBC
Complete Blood Count
CK
Creatinine Kinase
CPMP
Committee for Proprietary Medicinal Products (EU)
CRF
Case Report Form
CRO
Clinical Research Organization
CSA
Clinical Study Agreement
CSR
Clinical Study Report
CT
Computerized Tomography
CTCAE
Common Terminology Criteria for Adverse Event
DAE
Discontinuation of Investigational Product due to Adverse Event
DNA
Deoxyribonucleic Acid 
DTSQ
Diabetes Treatment Satisfaction Questionnaire
DTSQc
DTSQ Change Version
DTSQs
DTSQ Status Version
DXA
Dual Energy Xray Absorptiometry
ECG
Electrocardiogram
eCRF
Electronic Case Report Form
Ethics Committee
Synonymous to Institutional Review Board and Independent Ethics 
Committee
FBG
Fasting Blood Glucose
FDA
Food and Drug Administration (US)
FFA
Free Fatty Acid


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
14 (57)
Abbreviation or 
special term
Explanation
FSH
Follicle-stimulating Hormone
GCP
Good Clinical Practice
GMP
Good Manufacturing Practice
HDL-C
High-density Lipoprotein Cholesterol
HRT
Hormone replacement Therapy
ICH
International Conference on Harmonisation
IP
Investigational Product 
LDL-C
Low-density Lipoprotein Cholesterol
LIMS
Laboratory information management system
LOCF
Last Observation Carried Forward
LSLV
Last Subject Last Visit
N.B.
Nota Bene, mind you
OAD
Oral Antidiabetic Drug
OAE
Other Significant Adverse Event
pCRF
Paper Case Report Form
PGx
Pharmacogenetic research
PI
Principal Investigator 
PK
Pharmacokinetics
PPG 
Postprandial Plasma Glucose 
PPG AUC
Postprandial Glucose Area Under the Curve
PRO
Patient-reported Outcome
SAE
Serious Adverse Event (see definition in Section 6.2).
SDT
Study Delivery Team
SGLT1
Sodium-dependent Glucose Transporter 1
SGLT2
Sodium-dependent Glucose Transporter 2
SU
Sulphonylurea(s)
TG
Triglyceride
TSH
Thyroid-stimulating Hormone
UACR
Urine Albumin:Creatinine Ratio
ULN
Upper Limit of Normal
WBDC
Web Based Data Capture
WOCBP
Women of child bearing potential


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
15 (57)
1.
INTRODUCTION
1.1
Background and rationale for conducting this study
Metformin is recommended as a first-line therapy for patients with type 2 diabetes (T2DM). 
When glycemic control deteriorates, patients with T2DM usually require additional anti-
diabetic agents to control glycemia. Sulfonylureas (SUs) such as glimepiride are commonly 
added to metformin as a second-line treatment in clinical practice when metformin 
monotherapy cannot adequately control glycemia. However, SUs are frequently associated 
with unwanted side effects such as weight gain and hypoglycemia.
Therefore, in the present study, we would like to study the effect of dapagliflozin treatment for 
52 weeks on body composition in Korean T2DM subjects whose average body mass index 
(BMI) is around 25 kg/m2. The aim of this study is to compare the influence of dapagliflozin 
on body composition such as total-body fat mass (FM), abdominal visceral adipose tissue 
(VAT) and subcutaneous adipose tissue (SAT) volume compared with that of glimepiride. We 
expect that dapagliflozin treatment will decrease total body weight (TBW), and FM, whereas 
glimepiride increase them. We speculate in the present study that relative changes in body 
composition (i.e. fat mass vs. lean mass, VAT vs. SAT) may differ from those of the studies in 
Caucasians. In accordance with the changes of body composition, we predict that not only 
insulin resistance but also insulin secretion will improve in the dapagliflozin treatment group.
Until now, there has not been any comparative study about the influences of dapagliflozin vs. 
glimepiride in this area. Considering SUs are widely used in Asians, especially in Koreans, 
comparison of dapagliflozin vs. glimepiride on the changes of body composition, and insulin 
resistance and insulin secretion will give an important clinical implication in the management 
of diabetes, particularly in non-obese Koreans.
1.2
Rationale for study design, doses and control groups
Parallel group study design was chosen. In order maintain the practicality of the phase IV 
study, open label design of study drug delivery was chosen. The reading of the DXA scans 
will be conducted by one expert in blinded manner.
Glimepiride is the most frequently used SUs in Korea and therefore this was chosen as 
comparator.
Dapagliflozin treatment will be associated with reduction of total body FM, BW, abdominal 
VAT and SAT volume compared with glimepiride.
1.3
Benefit/risk and ethical assessment
Dapagliflozin, a newly developed sodium-glucose cotransporter 2 (SGLT2) inhibitor, 
improved glycemic control in patients with T2DM when used as monotherapy or as add-on to 
metformin [1,2]. SGLT2 inhibitors can reduce hyperglycemia by increasing urinary glucose 


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
16 (57)
excretion [3]. Since the mechanism of SGLT2 inhibitors is independent of insulin action, 
dapagliflozin treatment is associated with a low risk of hypoglycemia as well as moderate 
weight loss compared with SUs treatment [4].
Recently, Bolinder et al. [5] have shown that dapagliflozin treatment was associated with 
reduction in TBW, waist circumference, total-body FM, abdominal VAT and SAT volume in 
patients with T2DM. In this study of obese Caucasian subjects whose average BMI was 32 
kg/m2, the two-thirds of weight loss observed with dapagliflozin treatment was attributable to 
the reduction in total fat mass as measured by DXA, and moreover, dapagliflozin significantly 
decreased both abdominal VAT and SAT volumes as measured by magnetic resonance 
spectroscopy. However, the influence of dapagliflozin on change of body composition has not 
been studied in Asians, who have lower BMI and relatively higher proportion of visceral fat 
mass compared to Caucasians. Recent data from the 2011 Korea National Health and 
Nutrition Examination Survey showed that about half of T2DM subjects in Korea are non-
obese, even with obesity defined as a BMI of more than 25 kg/m2 [6]. Moreover, Asians 
appear to have the high proportion of body fat and prominent abdominal obesity compared to 
Caucasians with similar BMI values [7,8].
While both insulin resistance and S-cell dysfunction are important components in the 
pathophysiology of T2DM, the relative contributions of these two factors appear to be 
variable in different populations [9]. In Asians, the contribution of impaired S-cell function has 
been suggested to play a more crucial role in the pathogenesis of T2DM compared with 
Caucasians. In a series of analysis of recent pancreatectomized samples from a Korean 
university hospital, the pancreatic S-cell mass in T2DM subjects was significantly reduced 
compared with BMI-matched normal subjects, and S-cell area correlated with some 
parameters of S-cell function [10,11]. This might be a reasonable explanation for the fact that 
insulin secretagogues such as SUs are popular anti-hyperglycemic treatments in Asian diabetic 
patients. 
Compared with SUs, we do not know much about the influence of dapagliflozin on insulin 
secretion in patients with T2DM. A recent study showed that dapagliflozin treatment had a 
beneficial effect on insulin resistance, but insulin secretion with only borderline significance 
[12]. In this study, dapagliflozin treatment was associated with improved insulin resistance 
which was evidenced by the reduction in TBW as well as a significant increase in glucose 
disappearance rate during hyperinsulinemic euglycemic clamps. The borderline increase in 
insulin secretion might be secondary to the improvement of insulin resistance. However, it has 
not been thoroughly studied yet.
1.4
Study Design 
This is a 52 weeks, randomized, open-label, parallel-group, multi-centres phase IV study. 
Participants will be randomized 1:1 to receive dapagliflozin 10 mg qd or glimepiride 1~2 mg 
qd in an open-label manner for 12 months as add-on to metformin 1000 mg. 


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
17 (57)
Figure 1
Study Flow Chart
2.
STUDY OBJECTIVES
2.1
Primary objective
Primary Objective:
Outcome Measure:
To evaluate the effect of dapagliflozin on 
body composition in Korean T2DM 
subjects.
Changes in total body fat mass from baseline 
using DXA scan in 52 weeks after the start of the 
treatment 
2.2
Secondary objectives
Secondary Objective:
Outcome Measure :
To evaluate the efficacy in improving 
glycaemic control of dapagliflozin 
compared to glimepiride in subjects with 
type 2 diabetes.
The change in HbA1c levels from baseline to 52 
weeks (baseline, 12, 24, 36 and 52 weeks)
The proportion of Subjects achieving a glycemic 
response, defined as HbA1c <7.0% at Week 52
The change in FBS levels from baseline to 52 
weeks 52 weeks (baseline, 4, 12, 24, 36 and 52 
weeks)
Evaluate the effect on body weight of 
dapagliflozin compared to glimepiride in 
subjects with type 2 diabetes.
Changes in body weight, waist circumference, 
BMI from baseline 52 weeks (baseline, 4, 12, 24, 
36 and 52 weeks)
Evaluate the effect on blood pressure of 
dapagliflozin compared to glimepiride in 
subjects with type 2 diabetes.
Changes in SBP and DBP from baseline 52 
weeks (baseline, 4, 12, 24, 36 and 52 weeks)
Evaluate the effect on adipose tissue and 
lean volume of dapagliflozin compared to 
glimepiride in subjects with type 2 
Changes in abdominal VAT and SAT volume, 
VAT/SAT ratio using abdominal CT from 
baseline (baseline, 52 weeks)


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
18 (57)
diabetes.
Changes in lean mass from baseline using Dual 
Energy X-ray Absorptiometry (DXA)  scan (baseline, 
52 weeks)
Evaluate the effect on insulin resistance of 
dapagliflozin compared to glimepiride in 
subjects with type 2 diabetes.
Changes in hsCRP and adiponectin from baseline 
(baseline, 52 weeks)
2.3
Safety objectives
Safety Objective:
Outcome Measure :
Evaluate the safety of dapagliflozin and 
glimepiride.
Changes in CBC, electrolytes, lipid, urinalysis from 
baseline 52 weeks (baseline, 4, 12, 24, 36 and 52 
weeks)
Number, frequency and proportion of Subjects 
exposed to  adverse events
Number, frequency and proportion of Subjects 
exposed to  hypoglycemic events
2.4
Exploratory objectives  
Not applicable
3.
SUBJECT SELECTION, ENROLMENT, RANDOMISATION, 
RESTRICTIONS, DISCONTINUATION AND WITHDRAWAL 
Each subject should meet all of the inclusion criteria and none of the exclusion criteria for this 
study.  Under no circumstances can there be exceptions to this rule.
3.1
Inclusion criteria
For inclusion in the study subjects should fulfil the following criteria:
1.
Adults with T2DM (Male or female, O 19 and U 75 yrs)
2.
Patients in insufficient glycemic control (HbA1c > 7.0% and < 10.0% in recent 4 
weeks) 
3.
Patients with an unchanged dose of metformin (O 1,000 mg/day) for > 8 weeks prior 
to randomization
4.
Written informed consent


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
19 (57)
5.
WOCBP must take precautions to avoid pregnancy throughout the study and for 4 
weeks after intake of the last dose. 
!
WOCBP must have a negative urine pregnancy test at screening visit WOCBP 
include any female who has experienced menarche and who has not undergone 
successful surgical sterilization (hysterectomy, bilateral tubal ligation or 
bilateral oophorectomy) or is not postmenopausal.
!
WOCBP must be willing to use a medically accepted method of contraception 
that is considered reliable in the judgment of the Investigator.
3.2
Exclusion criteria
Subjects should not enter the study if any of the following exclusion criteria are fulfilled:
1.
Type 1 diabetes or history of diabetic ketoacidosis
2.
Pregnant or breast-feeding patients
3.
eGFR < 60 mL/min/1.73 m2 (MDRD) on visit 1.
4.
Indication of active liver disease (AST/ALT/total bilirubin > 3 X upper limits of 
normal) on visit 1.
5.
Acute coronary syndrome, stroke or TIA within 3 months prior to randomization
6.
Bariatric surgery within 2 years; treatment of anti-obesity drugs 3 months prior to 
randomization; any treatment leading to unstable body weight. (Unstable body 
weight is considered reliable in the judgment of the Investigator.)
7.
Any kind of surgery using foreign metallic materials
8.
History of bladder cancer or history of radiation therapy to the lower abdomen or 
pelvis at any time
9.
History of any other malignancy within 5 years (with the exception of successfully 
treated non-melanoma skin cancers)
10.
History of alcohol or drug abuse judged by physician within 3 months prior to 
randomization
11.
Concomitant participation in any other clinical study.
Procedures for withdrawal of incorrectly enrolled subjects see Section 3.4.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
20 (57)
3.3
Subject enrolment and randomization
120 subjects meeting all inclusion and none of the exclusion criteria will be randomized to the 
study. Estimated number of enrolled patients is approximately 160.
Subjects will be in open label treatment.
Subjects who discontinue the study will not be replaced.
The E-code is the only subject identification number to be used in CSRs and high level 
documents.
Investigator(s) should keep a record, the subject screening log, of subjects who entered pre-
study screening.
The Investigator(s) will:
1.
Obtain signed informed consent from the potential subject before any study specific 
procedures are performed.
2.
Assign potential subject a unique enrolment number code.
3.
Determine subject eligibility.
4.
Randomize only eligible subjects
If a subject withdraws from participation in the study, then his/her enrolment code cannot be 
reused.
Randomization will be conducted strictly sequentially as subjects become eligible for 
randomization.
3.4
Procedures for handling incorrectly enrolled or randomized 
subjects
Subjects who fail to meet the eligibility criteria should not, under any circumstances, be 
enrolled or receive study medication.  There can be no exceptions to this rule.  Subjects who 
are enrolled, but subsequently found not to meet all the eligibility criteria must not be 
randomized or initiated on treatment, and must be withdrawn from the study.
Where a subject does not meet all the eligibility criteria but is randomized in error, or 
incorrectly started on treatment, the Investigator should inform the AstraZeneca study 
physician immediately, and a discussion should occur between the AstraZeneca study 
physician and the investigator regarding whether to continue or discontinue the patient from 
treatment. The AstraZeneca study physician must ensure all decisions are appropriately 
documented.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
21 (57)
3.5
Methods for assigning treatment groups
Biostatistics group in CRO has the responsibility to generate the randomization scheme. The 
randomization scheme in blocks will be generated by computer software incorporating a 
random number generator. The randomization scheme can be balanced in blocks across the 
study.
3.6
Methods for ensuring blinding
Not applicable – This is an open-label study.
3.7
Methods for unblinding 
Not applicable – This is an open label study.
3.8
Restrictions
Subjects should be instructed to abstain from all food and recommended not to use
tobacco/nicotine products within 12 hours prior to each clinic visit and refrain from alcohol
intake 24 hours prior to the visits (drinking water after midnight is allowed). Acceptable
concomitant medications can be taken with water only.
Subjects should not take the investigational product and open-label metformin (and rescue
medication if applicable) on the morning of the clinic visit.
If a subject comes to a visit without having followed the above instructions, then the subject 
will be re-scheduled for the entire visit (if possible within allowed time-window).
Subjects who are blood donors should not donate blood from enrolment until 12 weeks
following their last dose of randomized treatment.
3.9
Discontinuation of investigational product
Subjects may be discontinued from investigational product (IP) in the following situations:

Subject decision.  The subject is at any time free to discontinue treatment, without 
prejudice to further treatment

Adverse Event (including laboratory abnormality or intercurrent illness) which, in the 
opinion of the investigator, indicates that continued participation in the study is not in 
the best interest of the subject

Major and/or frequent hypoglycaemic events, defined as O1 major event or recurring 
minor events (any recurrent events of hypoglycaemia, as judged by the investigator, 
not meeting the definition of major hypoglycaemic event)


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
22 (57)

Calculated Creatinine-Clearance <60 ml/min or an increase in serum creatinine of 
O0.5 mg/dl above the baseline value confirmed at a repeated measurement within one 
week.

Subject will become pregnant

Use of (need for) any antihyperglycaemic medication other than investigational 
product and metformin. Insulin use for up to 14 days total during the study and up to 
7 continuous days is permitted only in cases where:
!
Subjects are unable to take oral medications (for example during a 
gastrointestinal illness),
!
There is a documented illness or infection that requires additional therapy for 
maintaining glycaemic control.

Severe non-compliance with the study protocol.
3.9.1
Procedures for discontinuation of a subject from investigational product 
At any time, subjects are free to discontinue investigational product or withdraw from the 
study (i.e., investigational product and assessments), without prejudice to further treatment.  A 
subject that decides to discontinue investigational product will always be asked about the 
reason(s) and the presence of any adverse events.  If possible, they will be seen and assessed 
by an Investigator(s). Adverse events will be followed up (See Section 6) and all study drugs 
should be returned by the subject.
Randomized subjects who discontinue the study prematurely should immediately stop taking 
investigational product and complete the procedures described for Visit 7 (End of Treatment 
Visit), as soon as possible but not later than 7 days after discontinuation of investigational 
product. DXA and CT measurement should be performed as described for Visit 7.
If a subject is withdrawn from study, see Section 3.10.
3.10
Criteria for withdrawal 
3.10.1
Screen failures 
Screening failures are patients who do not fulfil the eligibility criteria for the study, and 
therefore must not be randomized.  These patients should have the reason for study 
withdrawal recorded as ‘Incorrect Enrolment’ (i.e., patient does not meet the required 
inclusion/exclusion criteria).  This reason for study withdrawal is only valid for screen failures 
(not randomized patients).
3.10.2
Withdrawal of the informed consent
Patients are free to withdraw from the study at any time (investigational product and 
assessments), without prejudice to further treatment.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
23 (57)
Patients who withdraw consent for further participation in the study will not receive any 
further IP or further study observation. Note that the patient may be offered additional tests to 
withdraw safely. 
A patient who withdraws consent will always be asked about the reason(s) and the presence of 
any adverse events (AE).  The Investigator will follow up AEs outside of the clinical study. 
If a subject withdraws from participation in the study, then his/her enrolment/randomization 
code cannot be reused. Withdrawn subjects will not be replaced. 
Patients will be considered lost to follow-up only if no contact has been established by the 
time the study is completed, such that there is insufficient information to determine the 
patient’s status at that time. Patients who refuse continuing participation in the study, 
including telephone contact, should be documented as “withdrawal of consent” rather than 
“lost to follow-up.”  Investigators should document attempts to re-establish contact with 
missing patients throughout the study period.  If contact with a missing patient is 
re-established, the patient should not be considered lost to follow-up and any evaluations 
should resume according to the protocol.
3.11
Discontinuation of the study
The study may be stopped if, in the judgment of AstraZeneca, study subjects are placed at 
undue risk because of clinically significant findings that:

meet individual stopping criteria or are otherwise considered significant 

are assessed as causally related to study drug, 

are not considered to be consistent with continuation of the study
Regardless of the reason for termination, all data available for the subject at the time of 
discontinuation of follow-up must be recorded in the CRF. All reasons for discontinuation of 
treatment must be documented.
In terminating the study, the Sponsor will ensure that adequate consideration is given to the 
protection of the subjects’ interests.
4.
STUDY PLAN AND TIMING OF PROCEDURES 
Study is planned to be conducted according to plan described in Table 1. 
This study is a 52-week, multi-centres, randomized, parallel-group, open, Phase IV study. All 
subjects will be enrolled by recruiting centres (centres treating patients with T2DM). Each 
enrolled subject will be referred to DXA measurement and abdominal CT scan.
The objectives of the study cover measurements at baseline, 4, 12, 24, 36 and 52 weeks. The 
primary efficacy end-point is to evaluate the effect of dapagliflozin 10 mg daily in 


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
24 (57)
combination with metformin compared to glimepiride in combination with metformin on body 
composition in Korean T2DM subjects after 52 weeks of oral administration of open-label 
treatment.
Subjects with T2DM and inadequate glycaemic control (HbA1c O7.0% and <10.0%) with 
stable metformin monotherapy O1000 mg/day for at least 8 weeks prior to enrolment will be 
eligible to enter the study.
The recruiting investigator will be the main point of contact for the subject and also 
responsible for the documentation of study data within the eCRF. All subjects do DXA 
measurement and abdominal scan scheduled to coincide with Visit 2 and Visit 7.
Local evaluation of the DXA will be conducted.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
25 (57)
Table 1
Study Plan detailing the procedures
Screening
(Baseline)
Randomi-
sation
Treatment
End of 
Therapy
Rescue 
Visit2
Study weeks
0wk (-7…0 
days)
0wk
4wks (+/- 7 
days)
12wks (+/- 7 
days)
24wks(+/- 7 
days)
36wks(+/- 7 
days)
52wks(+/- 7 
days)
Planned if 
needed
Visit
1
2
3
4
5
6
7
R
Informed consent
O
Demography
O
Physical Exam1
O
O
O
O
O
O
O
Medical/Surgical 
History
O
Diabetes History
O
12 lead ECG
O
O
Height
O
Weight
O
O
O
O
O
O
O
BMI calculation
O
O
O
O
O
O
O
Waist circumflex
O
O
O
O
O
O
O
Pulse, blood pressure 
(SPB/DBP)
O
O
O
O
O
O
O
FBG
O
O
O
O
O
O
O
HbA1C
O
O
O
O
O
O
CBC
O
O
O
O
AST/ALT/total 
bilirubin
O
O
O
O
O
BUN/creatinine
O
O
O
O
O
Na/K/Cl
O
O
O
O


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
26 (57)
Cholesterol/TG/HDL
O
O
O
Pregnancy test for all 
WOCBP
O
Urinalysis
O
O
O
O
O
O
O
hsCRP, adiponectin
O
O
O
Inclusion/exclusion 
criteria
O
O
Randomisation
O
Provide diet and life-
style counselling
O
O
O
O
O
O
O
DXA3
O 0wk 
(+0…7days)
O
CT4
O 0wk 
(+0…7days)
O
Dispense subject’s 
diary
O
O
O
O
O
O
Review subject’s diary
O
O
O
O
O
O
Dispense 
Investigational product
O
O
O
O
O
O
Drug accountability of
Investigational product
O
O
O
O
O
Dispense Metformin
O
O
O
O
O
Drug accountability of
Metformin
O
O
O
O
O
Check concomitant 
medication
O
O
O
O
O
O
O
Prescribe rescue 
medication5
O
O
O
O
O
O


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
27 (57)
Physical exam1 : cardiovascular, lungs, abdomen,  head, ears, eyes, nose, throat, and extremities
Rescue Visit2 : The rescue visit should take place as soon as possible but not later than 4 weeks after confirmation of repeated FBG and HbA1C. Rescue 
medication will be dispensed during rescue visit.
DXA3 : Standardization and level pre-check will be conducted prior to the start of the study. Whole-body DXA machines regardless of any manufacturer can 
be used in study sites.  
Abdominal CT4 : 1-cut pre-enhanced abdominal CT scan, standardization will be necessary prior to study. Reading of the scans will be conducted centrally.
Prescribe rescue medication5: any marketed sitagliptin in the dosage approved in Korea. Rescue medication should only be prescribed if required. See
Section 4.5.
Hypoglycaemic events
collection
O
O
O
O
O
O
Adverse Events 
collection
O
O
O
O
O
O
O
Serious Adverse 
Events collection
O
O
O
O
O
O
O
O


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
28 (57)
4.1
Screening: VISIT 1 
Procedures will be performed according to the Study Plan, see Table 1.
Patients will obtain information regarding the study and sign informed consent for the study 
before any study related procedures are initiated.
Consented patients will be assessed to ensure that they meet eligibility criteria.  
Demography, medical/surgical and diabetes history will be checked, 12 lead ECG will be 
conducted.
Physical exam will be conducted.
Height will be measured in cm (without shoes), weight in kg (light clothes and without shoes) 
and waist circumference (in cm). BMI calculation will be conducted. Pulse and blood pressure 
(SBP, DBP) will be measured.
Laboratory baseline test for efficacy and safety parameters will be conducted: FBG, HbA1c, 
CBC, AST, ALT, total bilirubin, BUN, creatinine, electrolytes, total cholesterol, triglyceride, 
HDL-cholesterol, urinalysis, hsCRP, adiponectin. All laboratory assessment will be done in 
central laboratory. Pregnancy test by dipstick should be performed for all WOCBP.
All serious adverse events occurring after signing the informed consent will be reported.
Concomitant diabetes and other medications will be checked.
Eligible patients will receive an enrolment code.
4.2
Randomization: VISIT 2
Eligibility criteria will be checked.
Subjects will be randomized to the treatment arm. Subjects who do not meet these criteria 
must not be randomized in the study.
DXA and abdominal CT baseline measurement will be conducted.
Diet and life-style counselling will be given to the subject.
Subjects will be given a diary to record hypoglycaemic events (symptoms).
All subjects will be instructed to constantly follow hygiene to avoid urinary tract infections.
Study drug will be dispensed according to randomisation.1mg glimepiride will be dispensed 
first to the subjects who are allocated to glimepiride group. Metformin will be dispensed.
All serious adverse events will be reported.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
29 (57)
Adverse Events will be collected from subject actually taking the IP.
4.3
Treatment Period: VISITS 3, 4, 5, 6
Physical exam contains measurement of weight, waist circumflex, pulse and blood pressure. 
BMI calculation will be conducted. 
Subject diary will be reviewed for hypoglycaemic events. New diary will be dispensed to the 
subjects.
Subjects will be followed for laboratory assessment of efficacy and safety according to study 
plan:

Visit 3: FBG, urinalysis

Visit 4: FBG, HbA1c, AST, ALT, total bilirubin, BUN, creatinine, urinalysis

Visit 5: FBG, HbA1c, CBC, AST, ALT, total bilirubin, BUN, creatinine, electrolytes, 
urinalysis

Visit 6 : FBG, HbA1c, urinalysis
All laboratory assessment will be done in central laboratory.
Diet and life-style counselling will be given to the subject.
Concomitant medications will be checked.
Drug accountability of investigational product and metformin will be conducted.
Investigational product and metformin will be dispensed.
In case of glimepiride group, glimepiride can be up titrated to 2 mg to maintain glycemic 
control at the discretion of the investigator after evaluation of glycaemic control in subjects. 
Glimepiride can be also down titrated to mitigate recurrent hypoglycaemic events at the 
discretion of the investigator but 0mg is not allowed. If further hypoglycaemic events occur 
with meeting the discontinuation criteria after taking the 1mg glimepiride, subjects may be 
discontinued from investigational product.
All serious adverse events will be reported.
Adverse Events will be collected from subject actually taking the IP.
Subjects will discontinue the study if one major hypoglycaemic event or recurring minor 
hypoglycaemic events (any recurrent events of hypoglycaemia, as judged by the investigator, 
not meeting the definition of major hypoglycaemic event) occur. 


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
30 (57)
Randomized subjects who discontinue the study prematurely should immediately stop taking 
investigational product and complete the procedures described for Visit 7.
4.4
End of Treatment: VISIT 7
Physical exam contains measurement of weight, waist circumflex, pulse and blood pressure. 
BMI calculation will be conducted.
12 lead ECG will be conducted.
Subjects will be followed for laboratory assessment of efficacy and safety according to study 
plan FBG, HbA1c, CBC, AST, ALT, total bilirubin, BUN, creatinine, electrolytes, total 
cholesterol, triglyceride, HDL-cholesterol, urinalysis, hsCRP, adiponectin. All laboratory 
assessment will be done in central laboratory.
Diet and life-style counselling will be given to the subject.
DXA and abdominal CT measurement will be conducted.
Concomitant medications will be checked.
Drug accountability of investigational product and metformin will be conducted.
Subject diary will be reviewed for hypoglycaemic events. 
All serious adverse events and adverse events will be reported and followed up
4.5
Lack of Glycaemic Control, Rescue Therapy
The subjects will receive investigational product during the entire randomized study period. 
All subjects will also continue to be provided with open-label 1000 mg metformin tablets with 
instructions to continue open-label metformin treatment for the duration of the study.
Randomized subjects with a central laboratory FBG and HbA1c value meeting the criteria for 
lack of glycaemic control during treatment period may be eligible to receive open-label, 
prescribed rescue medication which may allow the subject to remain in the trial. In case of 
subjects who are taking glimepiride, increase of dose to 2mg should be preceded first for 
glycaemic control. If there is lack of glycaemic control with meeting the rescue criteria though 
increase of dose to 2mg, rescue medication should be prescribed. 
Rescue therapy is open-label, any marketed sitagliptinin the dosage approved in Korea. 
Rescue medication should only be prescribed by investigator if required. No other rescue 
therapy is allowed. Treatment should be according local standards of care and approved 
prescribing guidance. All rescue decisions will be based on central laboratory fasting plasma 
glucose (FBG) and HbA1C.
Subjects who meet the following rescue criteria will be considered for rescue medication.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
31 (57)

Week 4 – 8 (excluding week 8) FBG >13.2 mmol/L (240 mg/dL)

Week 8 – 24 (including week 24) FBG >11.1 mmol/L (200 mg/dL)

Week 24 – Week 52 (including Week 52) HbA1c >8.0%
Randomized subjects who meet the repeated rescue criteria should be scheduled for a rescue 
visit. The rescue visit should take place as soon as possible but not later than 4 weeks after 
confirmation of repeated FBG and HbA1C. Rescue medication will be dispensed during 
rescue visit.
On rescue visit, following procedures will be conducted;
Physical exam contains measurement of weight, waist circumflex, pulse and blood pressure. 
BMI calculation will be conducted.
Subjects will be followed for laboratory assessment of efficacy and safety according to study 
plan FBG, HbA1c, CBC, AST, ALT, total bilirubin, BUN, creatinine, electrolytes, total 
cholesterol, triglyceride, HDL-cholesterol, urinalysis, hsCRP, adiponectin. All laboratory 
assessment will be done in central laboratory.
Diet and life-style counselling will be given to the subject.
Concomitant medications will be checked.
Subject diary will be reviewed for hypoglycaemic events. 
New diary will be dispensed to the subjects.
All serious adverse events and adverse events will be collected.The subjects will continue 
their study medication (investigational product and open-label metformin) as before and 
continue the original schedule for the visits during the remainder of the treatment period. 
Rescued subjects with central laboratory HbA1c values greater than HbA1c values specified 
per protocol, for 13 weeks despite rescue medication will be discontinued(Discontinuation 
criteria no. 1) from the study and referred for additional antihyperglycaemic therapy.
5.
STUDY ASSESSMENTS
Web Based Data Capture system will be used for data collection and query handling. The 
investigator will ensure that data are recorded on the electronic Case Report Forms as 
specified in the study protocol and in accordance with the instructions provided.
The investigator ensures the accuracy, completeness, and timeliness of the data recorded and 
of the provision of answers to data queries according to the Clinical Study Agreement.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
32 (57)
5.1
Efficacy assessments
5.1.1
Dual Energy X-Ray Absorptiometry (DXA)
Whole-body DXA will be used for the estimation of body composition. The relative 
attenuation of two different x-ray energies by body tissues produces a three-component model 
comprising total fat mass.
The DXA scans should be performed to evaluate the total body fat and lean mass according to 
the manufacturer’s manual for the DXA equipment, including the instructions for positioning, 
scan mode and specific information regarding the regions of interest.
Local evaluation will be done and whole-body DXA machines regardless of any manufacturer 
can be used in study sites. Standardization and level pre-check will be conducted prior to the 
start of the study.
5.1.2
CT
The CT scan will be performed using standard clinical scanners to evaluate abdominal VAT 
and SAT volume. 
Subcutaneous and visceral fat will be measured using a Multi-detector CT scan. The scans 
will be done at 100-120 kV, effective mAs. All the patients will be scanned in the 
craniocaudal or caudocranial direction while they are lying in the supine position with their 
arms above their head and legs elevated with a cushion.  We will acquire five 5-mm thickness
slices at the level of the umbilicus with 25mm and 50mm increment and analyzed for a cross-
sectional area of adipose tissue, which was expressed in centimeters squared. Areas will be 
calculated by multiplying the number of pixels of a given tissue type by the pixel number 
(pixel density). A post processing software (TeraRecon; TeraRecon, Inc., Foster City, CA) 
will be used for VAT and SAT volume measurement. The CT attenuation of fat will be 
defined as ranging from -190 to -30 HU. The parameters studied will include visceral fat 
amount (V) (cm2), subcutaneous fat amount (S) (cm2), V/V+S (%), and belly outer 
circumference (cm). Visceral fat was distinguished from subcutaneous abdominal fat by 
tracing along the fascial plane defining the internal abdominal wall. CT scan will not be 
conducted to the subjects who have contraindications to this procedure. 
5.1.3
Height, Weight and Waist Circumference
Height will be measured without shoes (in cm), weight will be measured with light clothes 
and without shoes (in kg). All readings should be recorded as accurately as possible and the 
same scale should be used for all assessments for a given subject.
The waist circumference (in cm) will be measured in the morning before breakfast. The waist 
circumference is measured midway between the lowest rib and the iliac crest. (WHO Report 
1987). Measurement should be made at the end of a normal expiration in a standing position 
and with measuring tape used in the study site.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
33 (57)
5.1.4
BMI
BMI will be computed by AstraZeneca.
BMI = weight/height2 (where weight is measured in kg, and height in metres). 
BMI will be calculated using the height measured at enrolment.
5.1.5
Pulse and Blood Pressure
One pulse measurement will be taken after the subject has been sitting and resting for at least 
5 minutes. Blood pressure will be measured using a standardized cuff adapted to the size of 
the subject’s arm while the subjects remain comfortably in a seated position with the arms 
raised to the level of the heart and in a supported position.
5.1.6
Physical Examination
A physical examination will include an assessment of the following: general appearance, 
respiratory, cardiovascular, abdomen, head and neck including head, ears, eyes, nose and 
throat).  The examination at Visit 1 is regarded as baseline data and new findings at the 
following physical examinations are recorded as change from baseline. Physical examination 
will also be performed in case of discontinuation of IP.  
5.1.7
Laboratory Efficacy Assessments
5.1.7.1
HbA1C
Blood sample for laboratory measurement of HbA1c will be performed at Visit 1, 4, 5, 6, 7 
and rescue visit. Laboratory assessments will be done at central laboratory.
5.1.7.2
Fasting Blood Glucose (FBG)
Blood sample for laboratory measurement of the concentration of glucose in the plasma after 
the patient has not eaten for 12 hours will be performed at Visit 1, 3, 4, 5, 6, 7 and rescue visit. 
Laboratory assessments will be done at central laboratory.
5.1.7.3
hsCRP and Adiponectin
Blood sample for laboratory measurement of hsCRP and adiponectin in the plasma after the 
patient has not eaten for 12 hours will be performed at Visit 1, 7 and rescue visit. Assessment 
will be done in central lab.
5.2
Safety assessments
5.2.1
Laboratory safety assessments
Blood sample for laboratory measurement will be performed at central laboratory.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
34 (57)
Table 2
Laboratory Safety Variables
Haematology/Haemostasis (whole blood)
Clinical Chemistry (serum or plasma)
B-Haemoglobin (Hb)
S/P-Creatinine
B-Leukocyte count
S/P-Bilirubin, total
B-Leukocyte differential count (absolute count)
S/P-Alkaline phosphatise (ALP)
B-Platelet count
S/P-Aspartate transaminase (AST)
S/P-Alanine transaminase (ALT)
Urinalysis (dipstick)
S/P-Albumin
U-Hb/Erythrocytes/Blood 
S/P-Potassium
U-Protein/Albumin 
S/P-Calcium, total
U-Glucose 
S/P-Sodium
S/P-Creatine kinase (CK)
5.2.2
12-Lead ECG
A 12-lead ECG will be taken (supine position, standard ECG with a recommended paper 
speed of 50 mm/second covering at least 6 sequential beats) after the subject has been lying 
down resting for at least 5 minutes. The ECG will be evaluated by the investigator and entered 
as “Normal” or “Abnormal” in the eCRF. If the ECG is evaluated as “Abnormal” the 
abnormality should be further specified.
5.2.3
Hypoglycemic Event
The subject will be asked to always self-monitor symptoms suggestive of hypoglycaemia and
to register any signs of hypoglycaemia in the supplied diary.
A hypoglycaemic event can be either

An episode with symptoms and confirmed low glucose.

An episode with low glucose.

An episode with symptoms when glucose was not measured.
For the evaluation of hypoglycaemic events special attention will be given to hypoglycaemia
as defined in accordance with CPMP guidance on clinical investigation of medicinal products
in the treatment of diabetes mellitus, as described below.

Major hypoglycaemic events, defined as symptomatic events requiring external 
assistance due to severe impairment in consciousness or behaviour, with a capillary 
or plasma glucose value <3.0 mmol/L (<54 mg/dL), and prompt recovery after 
glucose or glucagons administration.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
35 (57)

Minor hypoglycaemic event, defined as either a symptomatic event with a capillary 
or plasma glucose value <3.5 mmol/L (<63 mg/dL), and no need for external 
assistance, or an asymptomatic blood glucose measurement <3.5 mmol/L (<63 
mg/dL).

Events suggestive for hypoglycaemia, with symptoms that the subject experiences as 
hypoglycaemia and no confirmative measurement.
Data to be collected for each hypoglycaemic event:

Date of start and stop and time of the day for start

If symptoms are present or not and which symptoms

If finger stick value obtained and the plasma glucose value  

Intervention needed for recovery, max intensity, action taken, causality and possible 
contributing factors

Time of last drug administration

Time of last meal
The subject’s diary will be reviewed and data regarding hypoglycaemic events transcribed 
into the eCRFs at each clinical visit. A new diary for the next period will be handed over to 
the subject. If a major hypoglycaemic event occurs, or more than one minor event since last 
visit, the subject should contact the investigator. For recording of hypoglycaemic
events/symptoms suggestive of hypoglycaemic events as AEs, see Section 6.3.
5.3
Pharmacokinetics
Not applicable.
5.4
Pharmacodynamics
Not applicable.
5.5
Pharmacogenetics
Not applicable.
5.6
Biomarker analysis 
Not applicable. 


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
36 (57)
6.
SAFETY REPORTING AND MEDICAL MANAGEMENT
The Principal Investigator is responsible for ensuring that all staff involved in the study are 
familiar with the content of this section.
6.1
Definition of adverse events
An adverse event is the development of an undesirable medical condition or the deterioration 
of a pre-existing medical condition following or during exposure to a pharmaceutical product, 
whether or not considered causally related to the product.  An undesirable medical condition 
can be symptoms (e.g., nausea, chest pain), signs (e.g., tachycardia, enlarged liver) or the 
abnormal results of an investigation (e.g., laboratory findings, electrocardiogram).  In clinical 
studies, an AE can include an undesirable medical condition occurring at any time, including 
run-in or washout periods, even if no study treatment has been administered.
The term AE is used to include both serious and non-serious AEs.
6.2
Definitions of serious adverse event
A serious adverse event is an AE occurring during any study phase (ie screening, treatment, 
follow-up), that fulfils one or more of the following criteria:

Results in death

Is immediately life-threatening

Requires in-patient hospitalisation or prolongation of existing hospitalisation 

Results in persistent or significant disability/incapacity or substantial disruption of 
the ability to conduct normal life functions

Is a congenital abnormality or birth defect

Is an important medical event that may jeopardise the patient or may require medical 
intervention to prevent one of the outcomes listed above.
For further guidance on the definition of a SAE, see Appendix A to the Clinical Study 
Protocol.
6.3
Recording of adverse events
6.3.1
Time period for collection of adverse events
Adverse Events will be collected from subject actually taking the IP throughout the entire 
treatment period and during the follow-up period until the end of the study. SAEs will be 
collected from the time at which informed consent is obtained until the end of the study.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
37 (57)
6.3.2
Follow-up of unresolved adverse events
Any AEs that are unresolved at the patient’s last AE assessment in the study are 
followed up by the Investigator for as long as medically indicated, but without 
further recording in the eCRF. AstraZeneca retains the right to request additional 
information for any patient with ongoing AE(s)/SAE(s) at the end of the study, if 
judged necessary.
6.3.3
Variables 
The following variables will be collect for each AE;

AE (verbatim)

The date when the AE started and stopped

Maximum intensity

Whether the AE is serious or not

Investigator causality rating against the IP (yes or no)

Action taken with regard to investigational product

AE caused patient’s withdrawal from study (yes or no)

Outcome.
In addition, the following variables will be collected for SAEs:

Date AE met criteria for serious AE

Date Investigator became aware of serious AE

AE is serious due to

Date of hospitalisation

Date of discharge

Probable cause of death

Date of death

Autopsy performed

Causality assessment in relation to Study procedure(s)


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
38 (57)

Causality assessment in relation to Other medication

Description of AE.
It is important to distinguish between serious and severe AEs. Severity is a measure of 
intensity whereas seriousness is defined by the criteria in Section 6.2. An AE of severe 
intensity need not necessarily be considered serious.  For example, nausea that persists for 
several hours may be considered severe nausea, but not a SAE unless it meets the criteria 
shown in Section 6.2. On the other hand, a stroke that results in only a limited degree of 
disability may be considered a mild stroke but would be a SAE when it satisfies the criteria 
shown in Section 6.2.
Maximum intensity refers to the complete course of the AE.  The patient (parents/legal 
guardians) will be asked to assess the maximum intensity of the reported AEs according to the
following scale:

Mild (awareness of sign or symptom, but easily tolerated)

Moderate (discomfort sufficient to cause interference with normal activities)

Severe (incapacitating, with inability to perform normal activities).
6.3.4
Causality collection
The Investigator will assess causal relationship between Investigational Product and each 
Adverse Event, and answer ‘yes’ or ‘no’ to the question ‘Do you consider that there is a 
reasonable possibility that the event may have been caused by the investigational product?’
For SAEs causal relationship will also be assessed for other medication and study procedures.  
Note that for SAEs that could be associated with any study procedure the causal relationship is 
implied as ‘yes’.
A guide to the interpretation of the causality question is found in Appendix A to the Clinical 
Study Protocol.
6.3.5
Adverse events based on signs and symptoms
All AEs spontaneously reported by the patient or care provider or reported in response to the 
open question from the study personnel:  ‘Have you had any health problems since the 
previous visit/you were last asked?’, or revealed by observation will be collected and recorded 
in the eCRF. The question will be put to each patient (or parent/legal guardian) in local 
language from Visit 2 to the last follow-up telephone contact.  When collecting AEs, the 
recording of diagnoses is preferred (when possible) to recording a list of signs and symptoms.  
However, if a diagnosis is known and there are other signs or symptoms that are not generally 
part of the diagnosis, the diagnosis and each sign or symptom will be recorded separately.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
39 (57)
6.3.6
Adverse events based on examinations and tests
The results from protocol mandated laboratory tests, vital signs and other safety assessments 
will be summarized in the CSR. Deterioration as compared to baseline in these parameters 
will therefore only be reported as AEs if they fulfil any of the SAE criteria or are the reason 
for discontinuation of treatment with the investigational product. 
If deterioration in a laboratory value, vital sign or other safety assessment is associated with 
clinical signs and symptoms, the sign or symptom will be reported as an AE and the 
associated laboratory result or other finding will be considered as additional information. In 
the absence of clinical signs and symptoms, clinically relevant deteriorations in non-mandated 
parameters should be reported as AE(s). 
Any new or aggravated clinically relevant abnormal medical finding at a physical examination 
as compared with the baseline assessment will be reported as an AE.
6.4
Reporting of serious adverse events
All SAEs have to be reported, whether or not considered causally related to the investigational 
product, or to the study procedure(s). All SAEs will be recorded in the eCRF.
If any SAE occurs in the course of the study, then Investigators or other site personnel inform 
the appropriate AstraZeneca representatives within one day ie immediately but no later than 
24 hours of when he or she becomes aware of it. The designated AstraZeneca representative 
works with the Investigator to ensure that all the necessary information is provided to the 
AstraZeneca Patient Safety data entry site within 1 calendar day of initial receipt for fatal and 
life threatening events and within 5 calendar days of initial receipt for all other SAEs.
For fatal or life-threatening adverse events where important or relevant information is missing, 
active follow-up is undertaken immediately.  Investigators or other site personnel inform 
AstraZeneca representatives of any follow-up information on a previously reported SAE 
within one calendar day ie immediately but no later than 24 hours of when he or she becomes 
aware of it.
The AstraZeneca representative will advise the Investigator/study site personnel how to 
proceed. 
The reference document for definition of expectedness/listedness is the Product Information
for the Dapagliflozin Overdose.
6.5
Overdose
The risks associated with over dosage of Dapagliflozin are considered to be small.
In previously conducted clinical studies effects of overdose with dapagliflozin included severe 
nausea, severe vomiting and rapidly declining blood glucose concentrations. In the event of 
overdose, appropriate supportive treatment should be initiated according to the patient’s 
clinical signs and symptoms.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
40 (57)

An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE modules in the CRF and on the Overdose CRF module.

An overdose without associated symptoms is only reported on the Overdose CRF 
module.
If an overdose on an AstraZeneca study drug occurs in the course of the study, then the 
Investigator or other site personnel inform appropriate AstraZeneca representatives 
immediately, or no later than 24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative works with the Investigator to ensure that all 
relevant information is provided to the AstraZeneca Patient Safety data entry site.
For overdoses associated with a SAE, the standard reporting timelines apply, see Section 6.4.  
For other overdoses, reporting must occur within 30 days.
6.6
Pregnancy
All pregnancies and outcomes of pregnancy should be reported to AstraZeneca.
6.6.1
Maternal exposure
If a subject becomes pregnant during the course of the study investigational product should be 
discontinued immediately.
Pregnancy itself is not regarded as an adverse event unless there is a suspicion that the 
investigational product under study may have interfered with the effectiveness of a 
contraceptive medication.  Congenital abnormalities/birth defects and spontaneous 
miscarriages should be reported and handled as SAEs.  Elective abortions without 
complications should not be handled as AEs.  The outcome of all pregnancies (spontaneous 
miscarriage, elective termination, ectopic pregnancy, normal birth or congenital abnormality) 
should be followed up and documented even if the subject was discontinued from the study.
If any pregnancy occurs in the course of the study, then the Investigator or other site personnel 
informs the appropriate AstraZeneca representatives within 1day i.e., immediately but no 
later than 24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative works with the Investigator to ensure that all 
relevant information is provided to the AstraZeneca Patient Safety data entry site within 1 or 5 
calendar days for SAEs (see Section 6.4) and within 30 days for all other pregnancies.
The same timelines apply when outcome information is available.
6.6.2
Paternal exposure 
There is no restriction on fathering children or donating sperm during the study.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
41 (57)
6.7
Management of IP related toxicities 
Treatment related toxicity is not expected from dapagliflozin, when used as directed.  For 
overdose, see Section 6.5.
6.8
Study governance and oversight
This section is not applicable.
7.
INVESTIGATIONAL PRODUCT AND OTHER TREATMENTS
7.1
Identity of investigational product(s)
Investigational Product
Dapagliflozin tablets, 10 mg, administered orally, once daily as add-on to metformin 1000 mg.
Comparator
Glimepiride tablets, 1 mg, administered orally 1 or 2 tablets (1mg or 2mg) as add-on to 
metformin 1000mg will be used at a dose of 1 to 2 mg/day with the up-titration. Glimepiride 
dose can be down-titrated at any time to prevent hypoglycemia.
Table 3
Investigational Products
Treatment
Dosage form and strength
Manufacturer
Dapagliflozin
Biconvex, diamond shape, 
green tablet 10 mg (Size: 11 
mm)
Bristol-Myers Squibb
Glimeperide 
Flat-faced, oblong tablet, with 
notched sides at the bisect, 
pink tablet 1 mg 
Sanofi Aventis
Table 4
Additional Drug
Treatment
Dosage form and strength
Manufacturer
Metformin
Film coated, white to off-white 
round tablet 1000 mg
Merck
7.2
Dose and treatment regimens
The investigational product, dapagliflozin or glimepiride, and additional drug, metformin 
1000 mg will be taken orally. 


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
42 (57)
Subjects to be allocated to the glimerpiride group will start taking 1mg glimepiride at visit 2. 
At visit 3, 4, 5 and 6, glimepiride can be up titrated to 2 mg to maintain glycemic control at 
the discretion of the investigator after evaluation of glycaemic control in subjects. Glimepiride 
can be down titrated to mitigate recurrent hypoglycaemic events at the discretion of the 
investigator but 0mg is not allowed. If further hypoglycaemic events occur with meeting the 
discontinuation criteria after taking the 1mg glimepiride, subjects may be discontinued from 
investigational product.
Dapagliflozin or glimepiride should be taken once daily, in the morning, as instructed by the 
investigator, immediately before or together with a meal.
The investigational product should be taken at approximately the same time of the day during 
the study period. The metformin should be taken just before or together with a meal according 
to the investigator’s instruction. 
Subjects should be instructed to abstain from all food and beverages for 12 hours prior to each 
clinical visit; however, drinking water after midnight is allowed. In the morning prior to each 
visit, acceptable concomitant medications can be taken with water only.
7.3
Labelling
IP for the study will be provided in commercially available packages with a study-specific 
label. Labels will be prepared in accordance with Good Manufacturing Practice (GMP) and 
local regulatory guidelines.  The labels will fulfil GMP Annex 13 requirements for labelling.  
Label text will be translated into local language.
7.4
Storage
All study drugs should be kept in a secure place under appropriate storage conditions.
7.5
Compliance
The administration of all study drugs (including investigational products) should be recorded 
in the appropriate sections of the eCRF.
7.6
Accountability
The study drug provided for this study will be used only as directed in the study protocol.
The study personnel will account for all study drugs dispensed to and returned from the 
subject.
AZ or its representative will oversee that study personnel account for IPs received at the study 
center, unused IP and IP for appropriate destruction. At the termination of the Clinical Study 
or at the request of AZ, the Investigator will either return any unused IP to AZ, or destroy 
investigational product at the site depending on local regulations. If the IP is destroyed at site, 
the site personnel will account for all unused IP and for appropriate destruction. If the IP is 


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
43 (57)
returned to AZ, the study site personnel or the AZ monitor will account for all received IP and 
return all unused IP to AZ. Certificates of delivery and return should be signed.
7.7
Concomitant and other treatments 
7.7.1
General Medication
Other medication than described in Exclusion Criteria Section 3.2, Discontinuation Criteria
Section 3.9, and Prohibited Medication Section 7.7.2, which are considered necessary for the 
subject’s safety and well-being (eg, to treat illnesses or complaints that occur during the 
study), may be given at the discretion of the investigator.
7.7.2
Prohibited Medication
Once enrolled, subjects must not receive any of the following for the duration of the study:

Antihyperglycaemic medication other than protocol required medication 
(investigational product, open-label metformin, and when necessary open-label 
marketed sitagliptin).

Insulin use for up to 14 days total during the study and up to 7 continuous days is 
permitted only in cases where:

Subjects are unable to take oral medication (for example during a gastrointestinal 
illness)

There is a documented illness or infection that requires additional therapy for 
maintaining glycaemic control

Subjects have to temporarily stop investigational product and/or open-label 
metformin due to requirements of this clinical study protocol. 
Also, insulin use for up to 7 days during hospitalization is allowed as long as the primary 
reason for hospitalization is not management of the subject’s glycaemic control.

Treatment with any systemic corticosteroid therapy that will involve >7 days of
therapy (two temporary periods of higher daily doses (equivalent to oral prednisolone 
>10 mg/day) but no longer than 7 days each are allowed). The AstraZeneca 
representative should be consulted prior to beginning therapy with corticosteroids for 
subjects who require systemic corticosteroid treatment.

Treatment with any medication that could have an influence on bone metabolism

Any anti-obesity medication

Hormone replacement therapy (not including local treatment)


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
44 (57)

Administration of sibutramine, phentermine, orlistat, rimonabant, benzphetamine, 
diethylpropion, methamphetamine, and/or phendimetrazine.
7.8
Post Study Access to Study Treatment
Study treatment is commercially available in Korea.
8.
STATISTICAL ANALYSES BY ASTRAZENECA
8.1
Statistical considerations

All personnel involved with the analysis of the study will remain blinded until 
database lock and protocol violators identified.

Analyses will be performed by AstraZeneca or its representatives.    
A comprehensive Statistical Analysis Plan (SAP) will be prepared prior to first subject 
randomized and any subsequent amendments will be documented.
8.2
Sample size estimate
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
5HGDFWHG


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
8.3
Definitions of analysis sets
8.3.1
Efficacy analysis set
Full Analysis Set (FAS)
The full analysis set will included all randomized subjects who receive at least one dose of 
study medication during the 52 week treatment period who have a non-missing baseline value 
and at least one post-baseline value for primary efficacy variable.
Whenever appropriate, missing values will be replaced by the last observation carried forward 
(LOCF) approach.
Whenever using the FAS, subjects will be presented in the treatment group to which they were 
randomized.
Per-Protocol Set (PPS)
The per-protocol set is a subset of the full analysis set consisting of subjects who do not 
violate the terms of the protocol, which may affect the efficacy endpoints significantly. All 
decisions to exclude subjects from the full analysis set to create the per-protocol set will be 
made prior to DB locking.
8.3.2
Safety analysis set
Safety analysis set will include all randomized subjects who received at least one dose of 
study medication during treatment period. Subjects who were dispensed the wrong 
randomized treatment will be counted in the treatment group for which they received 
medication. 
8.3.3
PK analysis set
Not applicable.
5HGDFWH
G
5HGDFW
HG
5HGDFW
HG
5HGDFW
HG
5HGDFW
HG
5HGDFWHG


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
46 (57)
8.3.4
PRO analysis set
Not applicable.
8.4
Outcome measures for analyses
Efficacy Variables

Change from Baseline: Change from baseline will be calculated as absolute 
difference between the values measured at a specific time point after baseline minus 
baseline value. Baseline value is defined to be Visit 2 (randomization).

Proportion of subjects achieving a glycemic response, defined as HbA1c<7.0% at 
Week 52.
If no measurements is available at Week 52, the last post-baseline HbA1c prior to Week 52 
will be used instead for analysis.
Safety Variables
The following safety data will be collected: CBC, electrolytes, lipid, urinalysis, vital signs 
(pulse), reported hypoglycemic events and adverse events.
Change from screening (Visit 1) to each post-treatment time point where scheduled 
assessments were made will be calculated for CBC, electrolytes, lipid, and vital signs (pulse).
8.5
Methods for statistical analyses
8.5.1
Analysis of the primary variable (s)
The primary efficacy variable of the study is the change in total body fat mass from baseline 
using DXA scan in 52 weeks after the start of the treatment.
The null hypothesis H0 given below will be tested against the alternative hypothesis HA 
(\=0.05, two-sided).  The alternative hypothesis states that the difference between two 
treatment groups in the mean change from Baseline to Week 52 is not zero:
H0:  ]T-]C=0
versus
HA:  ]T-]C^0
where _T denotes the mean change in total body fat mass from Baseline to Week 52 in the 
group of patients treated with Dapagliflozin (active investigational product, T) and _C the 
mean change in total body fat mass from Baseline to Week 52 in the group of patients with 
Glimepiride (comparator, C).
The change from Baseline to Week 52 in total body fat mass will be analysed using 
ANCOVA model with treatment group as factor and Baseline total body fat mass as a 
covariate. The model will be used to derive a least squares estimate of the treatment difference 
in mean change with corresponding two-sided 95% confidence interval (CI) and two-sided p-


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
47 (57)
value.  Further, two-sided 95% CIs for the mean change within each treatment group will be 
calculated. 
8.5.2
Analysis of the secondary variable(s)
The statistical significance levels for secondary endpoints will not be adjusted for multiple 
hypothesis testing and will be interpreted only descriptively
Change in HbA1c Levels from Baseline to 52 Weeks
Change from baseline to each visit measurement for HbA1c will be analyzed by a MMRM)
method. All non-missing visit data will be used. The model will include terms for treatment 
group, visit, visit*treatment group and baseline measurement as a covariate. The model will 
be used to derive a least squares estimate of the treatment difference with 95% confidence 
interval and corresponding two-sided p-value. Missing data will not be imputed. 
Change in Body Weight, Waist Circumference, BMI from Baseline to 52 Weeks
For change in body weight, waist circumference, BMI from baseline to 52 weeks, a same 
manner of secondary efficacy variable (HbA1c) will be performed.
Change in SBP and DBP from Baseline to 52 Weeks
For change in SBP and DBP from baseline to 52 week, a same manner of secondary efficacy 
variable (HbA1c) will be performed.
The Proportion of Subjects Achieving a Glycemic Response, Defined as HbA1c<7.0% at 
Week 52
The proportion of subjects who achieved an HbA1c<7.0 at week 52 (LOCF) will be assessed 
using logistic regression analysis with treatment group as a factor and baseline HbA1c as a
covariate. 
The number and percentage of responders and non-responders will be also presented. The 
odds ratio and its 95% CI from logistic regression will be estimated.
Change in FBS Levels from Baseline to 52 Weeks
For change in FBS from baseline to 52 week, a same manner of secondary efficacy variable 
(HbA1c) will be performed.
Change in Abdominal VAT and SAT Volume, VAT/SAT Ratio Using Abdominal CT from 
Baseline
For change in abdominal VAT and SAT volume, VAT/SAT ratio using abdominal CT from 
baseline to 52 week, a same manner of primary efficacy variable will be performed.
Changes in lean mass from baseline using Dual Energy X-ray Absorptiometry (DXA) scan 
from baseline to 52 weeks)
For changes in lean mass from baseline using Dual Energy X-ray Absorptiometry (DXA) scan, 
a same manner of primary efficacy variable will be performed.
Change in hsCRP and Adiponectin from baseline to 52 Weeks


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
48 (57)
For change in hsCRP and adiponectin from baseline to 52 week, a same manner of primary 
efficacy variable will be performed.
Safety Analysis
All safety analysis will be based on safety analysis set.
Change in CBC, Electrolytes, Lipid, Urinalysis from Baseline to 52 Weeks
Changes from baseline to 52 weeks for each clinical laboratory test, including CBC, 
electrolytes, and lipid measurements will be summarized using descriptive statistics by 
treatment group. In addition, the number and percent of patients with a marked abnormality in 
clinical laboratory tests including CBC, electrolytes, lipid and urinalysis will be summarized 
by treatment group.
Differences between treatment groups will be interpreted in a descriptive manner.
Number, Frequency and Proportion of Subjects Exposed to Adverse Events
The focus of adverse event reporting in result tables will be on TEAEs.
The number and percent of patients with adverse events, leading to discontinuation of IP, 
serious adverse events and adverse drug reactions will be summarized by system organ class
(SOC) and preferred term for (PT) each treatment group using terms coded by MedDRA.
No statistical test will be performed to compare adverse event rates between treatment groups. 
Serious adverse events will be listed in detail.
Number, Frequency and Proportion of Subjects Exposed to Hypoglycemic Events
Subjects reporting at least one episode of a hypoglycemic event will be summarized by counts, 
proportions, and corresponding 95% confidence intervals. A comparison between the 
treatment groups will be performed using two-sided Fisher’s exact test.
8.5.3
Subgroup analysis 
Not applicable.
8.5.4
Interim analysis
No interim analyses are planned.
8.5.5
Sensitivity analysis 
Sensitivity analysis of the primary variable will be carried out and will be specified in the SAP.
8.5.6
Exploratory analysis 
Not applicable.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
49 (57)
9.
STUDY AND DATA MANAGEMENT BY ASTRAZENECA
9.1
Training of study site personnel
Before the first subject is entered into the study, an AstraZeneca representative will review 
and discuss the requirements of the Clinical Study Protocol and related documents with the 
investigational staff and also train them in any study specific procedures and system(s) 
utilised.
The Principal Investigator will ensure that appropriate training relevant to the study is given to 
all of these staff, and that any new information relevant to the performance of this study is 
forwarded to the staff involved.
The Principal Investigator will maintain a record of all individuals involved in the study 
(medical, nursing and other staff).
9.2
Monitoring of the study
During the study, an AstraZeneca representative will have regular contacts with the study site, 
including visits to:

Provide information and support to the Investigator(s)

Confirm that facilities remain acceptable

Confirm that the investigational team is adhering to the protocol, that data are being 
accurately and timely recorded in the CRFs, that biological samples are handled in 
accordance with the Laboratory Manual and that study drug accountability checks are 
being performed

Perform source data verification (a comparison of the data in the CRFs with the 
subject’s medical records at the hospital or practice, and other records relevant to the 
study) including verification of informed consent of participating subjects. This will 
require direct access to all original records for each subject (e.g., clinic charts)

Ensure withdrawal of informed consent to the use of the subject’s biological samples 
is reported and biological samples are identified and disposed of/destroyed 
accordingly, and the action is documented, and reported to the subject.
The AstraZeneca representative will be available between visits if the Investigator(s) or other 
staff at the centre needs information and advice about the study conduct.
9.2.1
Source data
Original patient data in study sites


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
50 (57)
9.2.2
Study agreements
The Principal Investigator at each/the centre should comply with all the terms, conditions, and 
obligations of the Clinical Study Agreement, or equivalent, for this study.  In the event of any 
inconsistency between this Clinical Study Protocol and the Clinical Study Agreement, the 
terms of Clinical Study Protocol shall prevail with respect to the conduct of the study and the 
treatment of subjects and in all other respects, not relating to study conduct or treatment of 
subjects, the terms of the Clinical Study Agreement shall prevail.
Agreements between AstraZeneca and the Principal Investigator should be in place before any 
study-related procedures can take place, or subjects are enrolled.
9.2.3
Archiving of study documents
The Investigator follows the principles outlined in the Clinical Study Agreement (CSA).
9.3
Study timetable and end of study
The end of the study is defined as ‘the last visit of the last subject undergoing the study’.
The study is expected to start in Q4 2015 and to end by Q2 2017
The study may be terminated at individual centres if the study procedures are not being 
performed according to GCP, or if recruitment is slow.  AstraZeneca may also terminate the 
entire study prematurely if concerns for safety arise within this study or in any other study 
with dapagliflozin.
9.4
Data management by delegate of AstraZeneca 
Data management will be performed by CRO, according to the Data Management Plan.  
Adverse events and medical/surgical history will be classified according to the terminology of 
the latest version the Medical Dictionary for Regulatory Activities (MedDRA).  Medications 
will be classified according to the AstraZeneca Drug Dictionary.  Classification coding will be 
performed by CRO.
The data collected through third party sources will be obtained and reconciled against study 
data.
Data queries will be raised for inconsistent, impossible or missing data.  All entries to the 
study database will be available in an audit trail.
The data will be validated as defined in the Data Management Plan.  Quality control 
procedures will be applied to each stage of data handling to ensure that all data are reliable 
and have been processed correctly.  The Data Management Plan will also clarify the roles and 
responsibilities of the various functions and personnel involved in the data management 
process


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
51 (57)
When all data have been coded, validated, <<signed>> and locked, clean file will be declared.  
Any treatment revealing data may thereafter be added and the final database will be locked.
Serious Adverse Event (SAE) Reconciliation
SAE reconciliation reports are produced and reconciled with the Patient Safety database 
and/or the investigational database. 
Data Management of genotype data
Not applicable.
10.
ETHICAL AND REGULATORY REQUIREMENTS
10.1
Ethical conduct of the study
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, applicable 
regulatory requirements and the AstraZeneca policy on Bioethics and Human Biological 
Samples.
10.2
Subject data protection
The Informed Consent Form will incorporate wording that complies with relevant data 
protection and privacy legislation.

Study data will be stored in a computer database, maintaining confidentiality in 
accordance with relevant data protection and privacy legislation

Patient data will be maintaining confidentiality in accordance with relevant data 
protection and privacy legislation 

For data verification purposes, authorised representatives of AstraZeneca, a 
regulatory authority, an IRB may require direct access to parts of the hospital or 
practice source records relevant to the study, including subjects’ medical history

All data computer processed by AstraZeneca will be identified by study code and 
enrolment code (E-code)
10.3
Ethics and regulatory review
An Institutional Review Board (IRB) should approve the final study protocol, including the 
final version of the Informed Consent Form and any other written information and/or 
materials to be provided to the subjects.  The Investigator will ensure the distribution of these 
documents to the applicable IRB, and to the study site staff.
The opinion of the IRB should be given in writing. The Investigator should submit the written 
approval to AstraZeneca before enrolment of any subject into the study. 


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
52 (57)
The IRB should approve all advertising used to recruit subjects for the study.
AstraZeneca should approve any modifications to the Informed Consent Form that are needed 
to meet local requirements.
Before enrolment of any subject into the study, the final study protocol, including the final 
version of the Informed Consent Form, is approved by the national regulatory authority or a 
notification to the national regulatory authority is done, according to local regulations.
AstraZeneca will handle the distribution of any of these documents to the national regulatory 
authorities.
AstraZeneca will provide Regulatory Authorities, IRB and Principal Investigators with safety 
updates/reports according to local requirements.
10.4
Informed consent
The Principal Investigator(s) at each centre will:

Ensure each subject is given full and adequate oral and written information about the 
nature, purpose, possible risk and benefit of the study

Ensure each subject is notified that they are free to discontinue from the study at any 
time

Ensure that each subject is given the opportunity to ask questions and allowed time to 
consider the information provided

Ensure each subject provides signed and dated informed consent before conducting 
any procedure specifically for the study

Ensure the original, signed Informed Consent Form(s) is/are stored in the 
Investigator’s Study File

Ensure a copy of the signed Informed Consent Form is given to the subject

Ensure that any incentives for subjects who participate in the study as well as any 
provisions for subjects harmed as a consequence of study participation are described 
in the informed consent form that is approved by an Ethics Committee.
The environment where the process of consent is conducted should be determined by the type 
of research being conducted but there should always be a period where a private, confidential, 
and “safe” setting is afforded to facilitate a constructive dialogue between the prospective 
subject and the person(s) involved in obtaining consent.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
53 (57)
10.5
Changes to the protocol and informed consent form
Study procedures will not be changed without the mutual agreement of the Principal 
Investigator and AstraZeneca.
If there are any substantial changes to the study protocol, then these changes will be 
documented in a study protocol amendment and where required in a new version of the study 
protocol (Revised Clinical Study Protocol).
The amendment is to be approved by the relevant IRB and if applicable, also the national 
regulatory authority approval, before implementation.  Local requirements are to be followed 
for revised protocols.
AstraZeneca will distribute any subsequent amendments and new versions of the protocol to 
each Principal Investigator(s). For distribution to IRB see Section 10.3.
If a protocol amendment requires a change to a centre’s Informed Consent Form, AstraZeneca 
and the centre’s IRB are to approve the revised Informed Consent Form before the revised 
form is used. 
If local regulations require, any administrative change will be communicated to or approved 
by each Ethics Committee.
Authorised representatives of AstraZeneca, a regulatory authority, or an Ethics Committee 
may perform audits or inspections at the centre, including source data verification.  The 
purpose of an audit or inspection is to systematically and independently examine all study-
related activities and documents, to determine whether these activities were conducted, and 
data were recorded, analysed, and accurately reported according to the protocol, Good Clinical 
Practice (GCP), guidelines of the International Conference on Harmonisation (ICH), and any 
applicable regulatory requirements.  The Investigator will contact AstraZeneca immediately if 
contacted by a regulatory agency about an inspection at the centre.


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
54 (57)
11.
LIST OF REFERENCES
1.
Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in 
type 2 diabetic patients with inadequate glycemic control by diet and exercise: a 
randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 
2010;33:2217-2224
2.
Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in 
patients with type 2 diabetes who have inadequate glycaemic control with 
metformin: a randomized, double-blind, placebo-controlled trial. Lancet 
2010;375:2223-2233
3.
Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment 
for diabetes mellitus. J Clin Endocrinol Metab 2010;95:34-42
4.
Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on 
therapy in patients with type 2 diabetes who have inadequate glycemic control with 
metformin: a randomized, 52-week, double-blind, active-controlled noninferiority 
trial. Diabetes Care 2011; 34:2015-2022 
5.
Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, 
total fat mass, and regional adipose tissue distribution in patients with type 2 
diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol 
Metab. 2012;97:1020-1031
6.
Kim CS, Ko SH, Kwon HS, Kim NH, Kim JH, Lim S, Choi SH, Song KH, Won JC, 
Kim DJ, Cha BY and Taskforce Team of Diabetes Fact Sheet of the Korean 
Diabetes Association. Prevalence, Awareness, and Management of Obesity in 
Korea: Data from the Korea National Health and Nutrition Examination Survey 
(1998-2011). Diabetes Metab J 2014;38(1):35-43
7.
Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY. 
Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368:1681-1688
8.
Ronald CWM, Juliana CNC. Type 2 diabetes in East Asians: similarities and 
differences in populations in Europe and the United States. Ann NY Acad Sci 
2013;1281:64-91
9.
Kahn SE. 2003. The relative contributions of insulin resistance and beta-cell 
dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3-19
10.
Yoon KH, Ko SH, Cho JH, et al. Selective beta-cell loss and alpha-cell expansion in 
patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 
2003;88:2300-08


Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
55 (57)
11.
Kim SK, Kim JH, Park JY, et al. Indexes of beta-cell function from the oral glucose 
tolerance test can modestly predict pancreatic beta-cell area in Korean. Diabetes 
Res Clin Pract 2011;93:220-227
12.
Mudaliar S, Henry RR, Boden G, Smith S, Chalamandaris AG, Duchesne D, Iqbal 
N, List J. Changes in insulin sensitivity and insulin secretion with the sodium 
glucose cotransporter 2 inhibitor dapagliflozin. Diabete Technol Ther 2014;16:1-8
13.
13. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, 
Canovatchel W, Meininger G. Efficacy and safety of canagliflozin versus 
glimepiride in patients with type 2 diabetes inadequately controlled with metformin 
(CANTATA-SU): 52 week results from a randomized, double-blind, phase 3 non-
inferiority trial. Lancet. 2013 Sep 14;382(9896):941-50


Clinical Study Protocol Appendix A
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
56 (57)
Appendix A
Additional Safety Information
Further Guidance on the Definition of a Serious Adverse Event (SAE)
Life threatening
‘Life-threatening’ means that the subject was at immediate risk of death from the AE as it 
occurred or it is suspected that use or continued use of the product would result in the 
subject’s death.  ‘Life-threatening’ does not mean that had an AE occurred in a more severe 
form it might have caused death (eg, hepatitis that resolved without hepatic failure).
Hospitalisation
Outpatient treatment in an emergency room is not in itself a serious AE, although the reasons 
for it may be (eg, bronchospasm, laryngeal oedema).  Hospital admissions and/or surgical 
operations planned before or during a study are not considered AEs if the illness or disease 
existed before the subject was enrolled in the study, provided that it did not deteriorate in an 
unexpected way during the study.
Important medical event or medical intervention
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important medical events may not be immediately life threatening or result in 
death, hospitalisation, disability or incapacity but may jeopardize the subject or may require 
medical intervention to prevent one or more outcomes listed in the definition of serious.  
These should usually be considered as serious.
Simply stopping the suspect drug does not mean that it is an important medical event; medical 
judgement must be used.

Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatment

Hepatotoxicity caused by paracetamol (acetaminophen) overdose requiring treatment 
with N-acetylcysteine

Intensive treatment in an emergency room or at home for allergic bronchospasm

Blood dyscrasias (eg, neutropenia or anaemia requiring blood transfusion, etc) or 
convulsions that do not result in hospitalisation
Development of drug dependency or drug abuse
A Guide to Interpreting the Causality Question
When making an assessment of causality consider the following factors when deciding if there 
is a ‘reasonable possibility’ that an AE may have been caused by the drug.


Clinical Study Protocol Appendix A
Drug Substance Dapagliflozin
Study Code D1690L00067
Version 3
Date 07 June 2016
57 (57)

Time Course.  Exposure to suspect drug.  Has the subject actually received the suspect 
drug?  Did the AE occur in a reasonable temporal relationship to the administration of 
the suspect drug?

Consistency with known drug profile.  Was the AE consistent with the previous 
knowledge of the suspect drug (pharmacology and toxicology) or drugs of the same 
pharmacological class? Or could the AE be anticipated from its pharmacological 
properties?

De-challenge experience.  Did the AE resolve or improve on stopping or reducing the 
dose of the suspect drug?

No alternative cause.  The AE cannot be reasonably explained by another aetiology 
such as the underlying disease, other drugs, other host or environmental factors.

Re-challenge experience.  Did the AE reoccur if the suspected drug was reintroduced 
after having been stopped? AstraZeneca would not normally recommend or support a 
re-challenge.

Laboratory tests.  A specific laboratory investigation (if performed) has confirmed the 
relationship.
In difficult cases, other factors could be considered such as:

Is this a recognized feature of overdose of the drug?

Is there a known mechanism?
Causality of ‘related’ is made if following a review of the relevant data, there is evidence for a 
‘reasonable possibility’ of a causal relationship for the individual case.  The expression 
‘reasonable possibility’ of a causal relationship is meant to convey, in general, that there are 
facts (evidence) or arguments to suggest a causal relationship.
The causality assessment is performed based on the available data including enough 
information to make an informed judgment.  With limited or insufficient information in the 
case, it is likely that the event(s) will be assessed as ‘not related’.
Causal relationship in cases where the disease under study has deteriorated due to lack of 
effect should be classified as no reasonable possibility.


'RFXPHQW1DPH


'RFXPHQW7LWOH






'RFXPHQW,'
 

9HUVLRQ/DEHO

                 







    
           



6HUYHU'DWH
GG000yyyy HH:mm ‘GMT’Z)
6LJQHG%\
0HDQLQJRI6LJQDWXUH

















































1RWHV 'RFXPHQWGHWDLOVDVVWRUHGLQ$1*(/DQ$VWUD=HQHFDGRFXPHQWPDQDJHPHQWV\VWHP
GOFVSYHQ
'/&OLQLFDO6WXG\3URWRFROYHUVLRQ(1
'RF,'

$SSURYHG
&855(17
/$7(67
-XQ*07
<RXQJVKLQ(XQ
4XDOLW\&RQWURO$SSURYDO
-XQ*07
.DULQ2WWHU
4XDOLW\$VVXUDQFH
$SSURYDO

SAP_000.pdf: 


6WDWLVWLFDO$QDO\VLV3ODQ

6WXG\&RGH
'/

(GLWLRQ1XPEHU
9

'DWH
)HEUXDU\














(IIHFWVRI'DSDJOLIOR]LQ&RPSDUHGZLWK*OLPHSLULGHRQ%RG\&RPSRVLWLRQ
LQ3DWLHQWVZLWK7\SH'LDEHWHV,QDGHTXDWHO\&RQWUROOHGZLWK0HWIRUPLQ

$VWUD=HQHFD0HGLFDO'LUHFWRU 

'DWH
4XLQWLOHV6WXG\6WDWLVWLFLDQ



'DWH

*OREDO3URGXFW6WDWLVWLFLDQ



'DWH





Redacte
d
Redacted


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

7$%/(2)&217(176
3$*(

7,7/(3$*(
7$%/(2)&217(176
/,672)$%%5(9,$7,216
$0(1'0(17+,6725<

678'<'(7$,/6

6WXG\REMHFWLYHV

6WXG\GHVLJQ

1XPEHURIVXEMHFWV

$1$/<6,66(76

'HILQLWLRQRIDQDO\VLVVHWV

$OO3DWLHQWV(QUROOHG6HW>(15@

$OO6XEMHFWV5DQGRPL]HG6HW>51'@

6DIHW\$QDO\VLV6HW>6$)@

)XOO$QDO\VLV6HW>)$6@

3HU3URWRFRO6HW>336@

9LRODWLRQVDQGGHYLDWLRQV

$/,672)0,12535272&2/'(9,$7,216:,//$/62%(
3529,'('$1$/<6,60(7+2'6

*HQHUDO3ULQFLSOHV

%DVHOLQHDQG&KDQJHIURP%DVHOLQH

5HIHUHQFH6WDUW'DWHDQG6WXG\'D\

5HWHVWV8QVFKHGXOHG9LVLWV(DUO\7HUPLQDWLRQ'DWDDQG5HVFXH9LVLW

0LVVLQJ'DWD

0XOWLFHQWHU6WXG\

0XOWLSOH&RPSDULVRQV0XOWLSOLFLW\

'LVSRVLWLRQDQGZLWKGUDZDOV

'HPRJUDSKLFVDQG2WKHU%DVHOLQH&KDUDFWHULVWLFV

'HULYDWLRQV

6XUJLFDO+LVWRU\0HGLFDO+LVWRU\DQG&RQFRPLWDQW3URFHGXUHV

0HGLFDWLRQV

6WXG\7UHDWPHQW([SRVXUHDQG&RPSOLDQFH

'HULYDWLRQV


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\


3ULPDU\(IILFDF\$QDO\VLV

3ULPDU\(IILFDF\9DULDEOH

3ULPDU\$QDO\VLVRI3ULPDU\(QGSRLQW

6HQVLWLYLW\$QDO\VLVRI3ULPDU\(QGSRLQW

6HFRQGDU\(IILFDF\$QDO\VHV

6HFRQGDU\(IILFDF\9DULDEOHV

3ULPDU\$QDO\VLVRI6HFRQGDU\(QGSRLQWV

6HQVLWLYLW\$QDO\VLVRI6HFRQGDU\(QGSRLQWV

6DIHW\$QDO\VHV

$GYHUVH(YHQWV$(V

,QWHQVLW\

5HODWLRQVKLSWR6WXG\7UHDWPHQW

$(V/HDGLQJWR6WXG\:LWKGUDZDO7UHDWPHQW'LVFRQWLQXDWLRQ

$(V/HDGLQJWR'RVH$GMXVWPHQWRU,QWHUUXSWLRQ

6HULRXV$(V6$(V

$(V/HDGLQJWR'HDWK

+\SRJO\FHPLF(YHQWVDQG+\SRJO\FHPLF$(V

'HDWKV

/DERUDWRU\(YDOXDWLRQV

(&*(YDOXDWLRQV

9LWDO6LJQV

3K\VLFDO([DPLQDWLRQV

&+$1*(62)$1$/<6,6)52035272&2/

5()(5(1&(6
$33(1',;/,672)352+,%,7('0(',&$7,216
$33(1',;352*5$00,1*&219(17,216)252873876



6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

/,672)$%%5(9,$7,216
$EEUHYLDWLRQRU
VSHFLDOWHUP

([SODQDWLRQ
ϭ
'ůǇĐĂƚĞĚŚĞŵŽŐůŽďŝŶ

ĚǀĞƌƐĞǀĞŶƚ
>d
ůĂŶŝŶĞŵŝŶŽƚƌĂŶƐĨĞƌĂƐĞ
^d
ƐƉĂƌƚĂƚĞŵŝŶŽƚƌĂŶƐĨĞƌĂƐĞ
D/
ŽĚǇDĂƐƐ/ŶĚĞǆ
D^
ƌŝƐƚŽůͲDǇĞƌƐ^ƋƵŝďď
W
ůŽŽĚWƌĞƐƐƵƌĞ

ŽŵƉůĞƚĞůŽŽĚŽƵŶƚ
<
ƌĞĂƚŝŶŝŶĞ<ŝŶĂƐĞ
WDW
ŽŵŵŝƚƚĞĞĨŽƌWƌŽƉƌŝĞƚĂƌǇDĞĚŝĐŝŶĂůWƌŽĚƵĐƚƐ;hͿ
Z&
ĂƐĞZĞƉŽƌƚ&Žƌŵ
ZK
ůŝŶŝĐĂůZĞƐĞĂƌĐŚKƌŐĂŶŝǌĂƚŝŽŶ
^
ůŝŶŝĐĂů^ƚƵĚǇŐƌĞĞŵĞŶƚ
^Z
ůŝŶŝĐĂů^ƚƵĚǇZĞƉŽƌƚ
d
ŽŵƉƵƚĞƌŝǌĞĚdŽŵŽŐƌĂƉŚǇ
E
ĞŽǆǇƌŝďŽŶƵĐůĞŝĐĐŝĚ
d^Y
ŝĂďĞƚĞƐdƌĞĂƚŵĞŶƚ^ĂƚŝƐĨĂĐƚŝŽŶYƵĞƐƚŝŽŶŶĂŝƌĞ
d^YĐ
d^YŚĂŶŐĞsĞƌƐŝŽŶ
d^YƐ
d^Y^ƚĂƚƵƐsĞƌƐŝŽŶ
y
ƵĂůŶĞƌŐǇyƌĂǇďƐŽƌƉƚŝŽŵĞƚƌǇ


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

$EEUHYLDWLRQRU
VSHFLDOWHUP

([SODQDWLRQ
'
ůĞĐƚƌŽĐĂƌĚŝŽŐƌĂŵ
ĞZ&
ůĞĐƚƌŽŶŝĐĂƐĞZĞƉŽƌƚ&Žƌŵ
ƚŚŝĐƐŽŵŵŝƚƚĞĞ
^ǇŶŽŶǇŵŽƵƐƚŽ/ŶƐƚŝƚƵƚŝŽŶĂůZĞǀŝĞǁŽĂƌĚĂŶĚ/ŶĚĞƉĞŶĚĞŶƚƚŚŝĐƐ
ŽŵŵŝƚƚĞĞ
&
&ŽŽĚĂŶĚƌƵŐĚŵŝŶŝƐƚƌĂƚŝŽŶ;h^Ϳ
&&
&ƌĞĞ&ĂƚƚǇĐŝĚ
&'
&ĂƐƚŝŶŐůŽŽĚ'ůƵĐŽƐĞ
&^,
&ŽůůŝĐůĞͲƐƚŝŵƵůĂƚŝŶŐ,ŽƌŵŽŶĞ
'W
'ŽŽĚůŝŶŝĐĂůWƌĂĐƚŝĐĞ
'DW
'ŽŽĚDĂŶƵĨĂĐƚƵƌŝŶŐWƌĂĐƚŝĐĞ
,>Ͳ
,ŝŐŚͲĚĞŶƐŝƚǇ>ŝƉŽƉƌŽƚĞŝŶŚŽůĞƐƚĞƌŽů
,Zd
,ŽƌŵŽŶĞƌĞƉůĂĐĞŵĞŶƚdŚĞƌĂƉǇ
/,
/ŶƚĞƌŶĂƚŝŽŶĂůŽŶĨĞƌĞŶĐĞŽŶ,ĂƌŵŽŶŝƐĂƚŝŽŶ
/W^
/ŶǀĞƐƚŝŐĂƚŝŽŶĂůWƌŽĚƵĐƚƐ
>>Ͳ
>ŽǁͲĚĞŶƐŝƚǇ>ŝƉŽƉƌŽƚĞŝŶŚŽůĞƐƚĞƌŽů
>K&
>ĂƐƚKďƐĞƌǀĂƚŝŽŶĂƌƌŝĞĚ&ŽƌǁĂƌĚ
E͘͘
EŽƚĂĞŶĞ͕ŵŝŶĚǇŽƵ
K
KƌĂůŶƚŝĚŝĂďĞƚŝĐƌƵŐ
ƉZ&
WĂƉĞƌĂƐĞZĞƉŽƌƚ&Žƌŵ
W<
WŚĂƌŵĂĐŽŬŝŶĞƚŝĐƐ
WW'
WŽƐƚƉƌĂŶĚŝĂůWůĂƐŵĂ'ůƵĐŽƐĞ
WW'h
WŽƐƚƉƌĂŶĚŝĂů'ůƵĐŽƐĞƌĞĂhŶĚĞƌƚŚĞƵƌǀĞ


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

$EEUHYLDWLRQRU
VSHFLDOWHUP

([SODQDWLRQ
WZK
WĂƚŝĞŶƚͲƌĞƉŽƌƚĞĚKƵƚĐŽŵĞ
^
^ĞƌŝŽƵƐĚǀĞƌƐĞǀĞŶƚ;ƐĞĞĚĞĨŝŶŝƚŝŽŶŝŶ^ĞĐƚŝŽŶϲ͘ϵͿ͘
^d
^ƵďĐƵƚĂŶĞŽƵƐĂĚŝƉŽƐĞƚŝƐƐƵĞ
^d
^ƚƵĚǇĞůŝǀĞƌǇdĞĂŵ
^'>dϭ
^ŽĚŝƵŵͲĚĞƉĞŶĚĞŶƚ'ůƵĐŽƐĞdƌĂŶƐƉŽƌƚĞƌϭ
^'>dϮ
^ŽĚŝƵŵͲĚĞƉĞŶĚĞŶƚ'ůƵĐŽƐĞdƌĂŶƐƉŽƌƚĞƌϮ
^h
^ƵůƉŚŽŶǇůƵƌĞĂ;ƐͿ
d'
dƌŝŐůǇĐĞƌŝĚĞ
d^,
dŚǇƌŽŝĚͲƐƚŝŵƵůĂƚŝŶŐ,ŽƌŵŽŶĞ
dϮD
dǇƉĞϮŝĂďĞƚĞƐDĞůůŝƚƵƐ
hZ
hƌŝŶĞůďƵŵŝŶ͗ƌĞĂƚŝŶŝŶĞZĂƚŝŽ
h>E
hƉƉĞƌ>ŝŵŝƚŽĨEŽƌŵĂů
sd
sŝƐĐĞƌĂůĂĚŝƉŽƐĞƚŝƐƐƵĞ
t
tĞďĂƐĞĚĂƚĂĂƉƚƵƌĞ
tKW
tŽŵĞŶŽĨĐŚŝůĚďĞĂƌŝŶŐƉŽƚĞŶƚŝĂů




6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

$0(1'0(17+,6725<
'DWH
%ULHIGHVFULSWLRQRIFKDQJH
-DQ
$8*
1$)LUVW9HUVLRQ
6HQVLWLYLW\$QDO\VLVDUHDGGHGDVVXSSRUWLYHDQDO\VLVWRDVVHVVWKHLPSDFWRQ
JHQGHUUDWLRRQSULPDU\DQGVHFRQGDU\HQGSRLQWV







6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\


678'<'(7$,/6
7KLVVWDWLVWLFDODQDO\VLVSODQ6$3SURYLGHVDGHWDLOHGGHVFULSWLRQRIWKHVWDWLVWLFDOPHWKRGV
SURSRVHGLQWKHVWXG\SURWRFRO)HEUXDU\GDWHGRQ-81YHUVLRQ

6WXG\REMHFWLYHV
7KHSULPDU\REMHFWLYHRIWKHVWXG\LVWRHYDOXDWHWKHHIIHFWRI'DSDJOLIOR]LQFRPSDUHGWR
*OLPHSLULGHRQERG\FRPSRVLWLRQLQ.RUHDQ7\SH'LDEHWHV0HOOLWXV7'0VXEMHFWVE\
DVVHVVLQJWKHFKDQJHVLQWRWDOERG\IDWPDVVIURPEDVHOLQHXVLQJ';$VFDQLQZHHNVDIWHU
WKHVWDUWRIWKHWUHDWPHQW
7KHUHDUHPXOWLSOHVHFRQGDU\REMHFWLYHVLQWKLVVWXG\
7RHYDOXDWHWKHHIILFDF\LQLPSURYLQJJO\FDHPLFFRQWURORI'DSDJOLIOR]LQFRPSDUHGWR
*OLPHSLULGHLQVXEMHFWVZLWKW\SHGLDEHWHVE\IROORZLQJDVVHVVPHQWV
x 7KHFKDQJHLQ+E$FOHYHOVIURPEDVHOLQHWRZHHNVEDVHOLQHDQG
ZHHNV
x 7KHSURSRUWLRQRIVXEMHFWVDFKLHYLQJDJO\FHPLFUHVSRQVHGHILQHGDV+E$FDW
:HHN
x 7KHFKDQJHLQ)%6OHYHOVIURPEDVHOLQHWRZHHNVEDVHOLQHDQG
ZHHNV
7RHYDOXDWHWKHHIIHFWRQERG\ZHLJKWRI'DSDJOLIOR]LQFRPSDUHGWR*OLPHSLULGHLQVXEMHFWV
ZLWKW\SHGLDEHWHVE\DVVHVVLQJFKDQJHVLQERG\ZHLJKWZDLVWFLUFXPIHUHQFH%0,IURP
EDVHOLQHWRDQGZHHNV
7RHYDOXDWHWKHHIIHFWRQEORRGSUHVVXUHRI'DSDJOLIOR]LQFRPSDUHGWR*OLPHSLULGHLQVXEMHFWV
ZLWKW\SHGLDEHWHVE\DVVHVVLQJFKDQJHVLQ6%3DQG'%3IURPEDVHOLQHDQG
ZHHNV
7RHYDOXDWHWKHHIIHFWRQDGLSRVHWLVVXHDQGOHDQYROXPHRI'DSDJOLIOR]LQFRPSDUHGWR
*OLPHSLULGHLQVXEMHFWVZLWKW\SHGLDEHWHVE\DVVHVVLQJFKDQJHVLQDEGRPLQDO9$7DQG
6$7DUHD9$76$7UDWLRXVLQJDEGRPLQDO&7IURPEDVHOLQHWRZHHNVEDVHOLQH
ZHHNVDQGFKDQJHVLQOHDQPDVVIURPEDVHOLQHXVLQJ'XDO(QHUJ\;UD\$EVRUSWLRPHWU\
';$VFDQWRZHHNVEDVHOLQHZHHNV
7RHYDOXDWHWKHHIIHFWRQLQVXOLQUHVLVWDQFHRI'DSDJOLIOR]LQFRPSDUHGWR*OLPHSLULGHLQ
VXEMHFWVZLWKW\SHGLDEHWHVE\DVVHVVLQJFKDQJHVLQKLJKVHQVLWLYLW\&53KV&53DQG
DGLSRQHFWLQIURPEDVHOLQHWRZHHNVEDVHOLQHZHHNV
7RHYDOXDWHWKHVDIHW\RI'DSDJOLIOR]LQDQG*OLPHSLULGHE\IROORZLQJDVVHVVPHQWV
x &KDQJHVLQ&%&HOHFWURO\WHVOLSLGXULQDO\VLVIURPEDVHOLQHWRDQG
ZHHNV


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

x 1XPEHUIUHTXHQF\DQGSURSRUWLRQRIVXEMHFWVH[SRVHGWRDGYHUVHHYHQWV
x 1XPEHUIUHTXHQF\DQGSURSRUWLRQRIVXEMHFWVH[SRVHGWRK\SRJO\FHPLFHYHQWV

6WXG\GHVLJQ
7KLVLVDZHHNVUDQGRPL]HGRSHQODEHOSDUDOOHOJURXSPXOWLFHQWUHVSKDVH,9VWXG\WR
HYDOXDWHWKHHIIHFWVRI'DSDJOLIOR]LQFRPSDUHGZLWK*OLPHSLULGHRQERG\FRPSRVLWLRQLQ
SDWLHQWVZLWK7\SH'LDEHWHVLQDGHTXDWHO\FRQWUROOHGZLWK0HWIRUPLQSDUWLFLSDQWVZLOO
EHUDQGRPL]HGWRUHFHLYH'DSDJOLIOR]LQPJTGRU*OLPHSLULGHaPJTGLQDQRSHQ
ODEHOPDQQHUIRUPRQWKVDVDGGRQWR0HWIRUPLQPJ7KHVWXG\GHVLJQDQGSODQDUH
VXPPDUL]HGLQ)LJXUHEHORZDQG7DEOHLQVWXG\SURWRFRO
)LJXUH6WXG\)ORZ&KDUW


6FKHGXOHGYLVLWVRIWKHVWXG\LQFOXGHPHDVXUHPHQWVDWEDVHOLQHDQGZHHNV
6XEMHFWVZLWK7'0DQGLQDGHTXDWHJO\FDHPLFFRQWURO+E$FDQGKDYLQJ
VWDEOH0HWIRUPLQPRQRWKHUDS\PJGD\IRUDWOHDVWZHHNVSULRUWRHQUROPHQWZLOOEH
HOLJLEOHWRHQWHUWKHVWXG\6XEMHFWVHDUO\WHUPLQDWHRUFRPSOHWHVWXG\WUHDWPHQWZLOOQRWEH
IXUWKHUIROORZHGDIWHU(QGRI7UHDWPHQW(R79LVLW7DEOHLQVWXG\SURWRFROSURYLGHVD
GHWDLOHGVFKHGXOHRIDVVHVVPHQWVRIHYHQWVUHODWHGWRWKHVWXG\REMHFWLYH

1XPEHURIVXEMHFWV
7RHYDOXDWHWKHHIIHFWRI'DSDJOLIOR]LQRQERG\FRPSRVLWLRQLQ.RUHDQ7'0VXEMHFWV




Redacted


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\


$1$/<6,66(76

'HILQLWLRQRIDQDO\VLVVHWV
3DWLHQWLQFOXVLRQLQHDFKRIWKHDQDO\VLVVHWVZLOOEHILQDOLVHGSULRUWRGDWDEDVHORFN)RU
DQDO\VHVDQGGLVSOD\VEDVHGRQ6DIHW\$QDO\VLV6HW6$)VXEMHFWVZLOOEHFODVVLILHG
DFFRUGLQJWRWKHDFWXDOWUHDWPHQWWKH\UHFHLYHG$OORWKHUDQDO\VHVZLOOEHSHUIRUPHGEDVHGRQ
WUHDWPHQWJURXSWRZKLFKVXEMHFWVZHUHUDQGRPL]HG

$OO3DWLHQWV(QUROOHG6HW>(15@
7KHDOOSDWLHQWVHQUROOHG(15VHWZLOOLQFOXGHDOOSDWLHQWVZKRJDYHFRQVHQWWRSDUWLFLSDWHLQ
WKHVWXG\

$OO6XEMHFWV5DQGRPL]HG6HW>51'@
7KHDOOVXEMHFWVUDQGRPL]HG51'VHWZLOOFRQWDLQDOOVXEMHFWVLQWKH(15VHWZKRZHUH
UDQGRPL]HGWRRQHRIWKHWUHDWPHQWDUPV

6DIHW\$QDO\VLV6HW>6$)@
7KHVDIHW\DQDO\VLVVHW>6$)@ZLOOLQFOXGHDOO51'VXEMHFWVZKRUHFHLYHGDWOHDVWRQHGRVHRI
VWXG\PHGLFDWLRQGXULQJWUHDWPHQWSHULRG
,IWKHUHLVDQ\GRXEWZKHWKHUDVXEMHFWZDVWUHDWHGRUQRWWKH\ZLOOEHDVVXPHGWUHDWHGIRUWKH
SXUSRVHVRIDQDO\VLV
)RUDQDO\VHVEDVHGRQ6$)VXEMHFWVZKRZHUHGLVSHQVHGZLWKWKHZURQJWUHDWPHQWWUHDWPHQW
RWKHUWKDQWKHRQHWKH\DUHUDQGRPL]HGWRZLOOEHFRXQWHGLQWKHWUHDWPHQWJURXSIRUZKLFK
WKH\DFWXDOO\UHFHLYHGPHGLFDWLRQ

)XOO$QDO\VLV6HW>)$6@
7KHIXOODQDO\VLVVHW>)$6@ZLOOLQFOXGHDOO51'VXEMHFWVZKRUHFHLYHGDWOHDVWRQHGRVHRI
VWXG\PHGLFDWLRQGXULQJWKHZHHNWUHDWPHQWSHULRGDQGKDYHDQRQPLVVLQJEDVHOLQHYDOXH
DQGDWOHDVWRQHSRVWEDVHOLQHYDOXHIRUSULPDU\HIILFDF\YDULDEOHWRWDOERG\IDWPDVV
:KHQHYHUXVLQJWKH)$6VXEMHFWVZLOOEHSUHVHQWHGLQWKHWUHDWPHQWJURXSWRZKLFKWKH\ZHUH
UDQGRPL]HG

3HU3URWRFRO6HW>336@
7KHSHUSURWRFROVHW>336@LVDVXEVHWRIWKH)$6FRQVLVWLQJRIVXEMHFWVZKRGRQRWYLRODWHWKH
WHUPVRIWKHSURWRFROZKLFKPD\DIIHFWWKHHIILFDF\HQGSRLQWVVLJQLILFDQWO\UHOHYDQWSURWRFRO
GHYLDWRUV
$OOGHFLVLRQVWRH[FOXGHVXEMHFWVIURPWKH)$6VHWWRFUHDWHWKH336VHWZLOOEHPDGHSULRUWR
'%ORFNLQJ


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

:KHQHYHUXVLQJWKH336VXEMHFWVZLOOEHSUHVHQWHGLQWKHWUHDWPHQWJURXSWRZKLFKWKH\ZHUH
UDQGRPL]HG

9LRODWLRQVDQGGHYLDWLRQV
3URWRFROGHYLDWLRQV3'VZLOOEHLGHQWLILHGYLDSURJUDPPLQJWRFRPSOHPHQWSURWRFRO
GHYLDWLRQORJ,IDSDWLHQWPHHWVDQ\RIWKHIROORZLQJFULWHULDWKHSDWLHQWZLOOEHUHYLHZHGDQG
PD\EHFRQVLGHUHGWREHDUHOHYDQWGHYLDWRUDQGFRQVHTXHQWO\DOOGDWDIRUWKDWSDWLHQWZLOOEH
H[FOXGHGIURPWKH336SRSXODWLRQ$OOUHOHYDQWDQGLUUHOHYDQWPDMRUFULWLFDOSURWRFRO
GHYLDWLRQVZLOOEHWDEXODWHGDQGOLVWHGDQGZLOOLQFOXGHEXWZLOOQRWEHOLPLWHGWR

3DWLHQWVIDLOLQJWRPHHWLQFOXVLRQH[FOXVLRQFULWHULDEXWPLVWDNHQO\UDQGRPL]HG

5DQGRPL]HGSDWLHQWVZKRIDLOHGWRUHFHLYHWUHDWPHQW

3URKLELWHGFRQFRPLWDQWPHGLFDWLRQV

5HFHLYLQJZURQJWUHDWPHQW

'HYHORSLQJZLWKGUDZDOFULWHULDZKLOVWRQWKHVWXG\EXWDUHQRWZLWKGUDZQ
3DWLHQWVZLWKSRRUWUHDWPHQWFRPSOLDQFHDUHGHILQHGDVWKRVHWDNLQJRU!RI
SODQQHG,QYHVWLJDWLQJ3URGXFW,37UHDWPHQWFRPSOLDQFHDOJRULWKPZLOOEHGLVFXVVHGLQD
VHSDUDWHVHFWLRQ
$OLVWRISURKLELWHGFRQFRPLWDQWPHGLFDWLRQVLVSURYLGHGLQWKHVWXG\SURWRFRO6HFWLRQ
&RUUHVSRQGGUXJQDPHVLVOLVWHGLQWKH$SSHQGL[RIWKH6$3
,IDSDWLHQWVDWLVILHVPRUHWKDQRQHRIWKHUHDVRQVIRUSURWRFROGHYLDWLRQOLVWHGDERYHDQGLV
MXGJHGWRKDYHERWKUHOHYDQWDQGLUUHOHYDQWGHYLDWLRQVWKHQVKHZLOOEHGHILQHGDVDUHOHYDQW
GHYLDWRU)RUWDEXODWLRQSXUSRVHVVKHZLOOEHFRXQWHGDVDUHOHYDQWGHYLDWRURQFHRYHUDOOEXW
DOVRRQFHZLWKLQHDFKGHYLDWLRQUHDVRQ
$VGUXJGLVSHQVHUHWXUQORVWLQIRUPDWLRQLVQRWFDSWXUHGRQ&5)FDOFXODWHGSRRUFRPSOLDQFH
GHILQHGDERYHZLOOEHSURJUDPPHGWRFRPSDUHZLWKSRRUWUHDWPHQWFRPSOLDQFHUHSRUWHGLQWKH
3'ORJ

$/,672)0,12535272&2/'(9,$7,216:,//$/62%(
3529,'('$1$/<6,60(7+2'6
6WDWLVWLFDOVXPPDULHVZLOOEHSHUIRUPHGE\4XLQWLOHV,06XVLQJ6$6YHUVLRQRUKLJKHU
DQGZKHUHDSSURSULDWHDGGLWLRQDOYDOLGDWHGVRIWZDUH


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\


*HQHUDO3ULQFLSOHV
$OOVDIHW\RXWFRPHVXPPDULHVZLOOEHSHUIRUPHGRQWKH6$)ZKLOVWDOOHIILFDF\DQDO\VHVZLOO
EHSHUIRUPHGRQ)$6RU336336IRUVHQVLWLYLW\DQDO\VHVRIHIILFDF\HQGSRLQWVXQOHVV
RWKHUZLVHVWDWHG,QDGGLWLRQWRWKHIRUPDOSUHVHQWDWLRQRIUHVXOWVGHWDLOHGLQWKHIROORZLQJ
VHFWLRQVDOOVWXG\GDWDZLOOEHOLVWHGE\FHQWUHSDWLHQWQXPEHUDQGWUHDWPHQWJURXS
)RUFRQWLQXRXVGDWDGHVFULSWLYHVWDWLVWLFVZLOOEHSUHVHQWHGIRUHDFKWUHDWPHQWJURXSDQG
RYHUDOOZKLFKLQFOXGHVQXPEHURISDWLHQWVQPHDQ6'PHGLDQPD[LPXPDQGPLQLPXP
XQOHVVRWKHUZLVHVSHFLILHG
)RUFDWHJRULFDOGDWDWKHIUHTXHQF\DQGSHUFHQWDJHRISDWLHQWVLQHDFKFDWHJRU\ZLOOEH
SUHVHQWHG&RXQWVWKDWDUH]HURZLOOEHGLVSOD\HGDV³´DQGDOOSHUFHQWDJHVZLOOEHEDVHGRQ
SRSXODWLRQVL]HRIHDFKWUHDWPHQWJURXSXQOHVVRWKHUZLVHVSHFLILHG
'DWDZLOOEHOLVWHGWRWKHVDPHDFFXUDF\DVUHFRUGHGLQWKHH&5)0HDQDQGPHGLDQVXPPDU\
VWDWLVWLFVZLOOEHSUHVHQWHGWRRQHDGGLWLRQDOGHFLPDOSODFHZKLOVWWKHVWDQGDUGGHYLDWLRQ6'
ZLOOEHSUHVHQWHGWRWZRDGGLWLRQDOGHFLPDOSODFHV0LQLPXPDQGPD[LPXPYDOXHVZLOOEH
SUHVHQWHGWRWKHVDPHDFFXUDF\DVUHFRUGHGRQWKHH&5)
7KHGHIDXOWVLJQLILFDQWOHYHORIVWDWLVWLFDOWHVWLQJZLOOEHFRQILGHQFHLQWHUYDOVZLOOEHWZR
VLGHGDQGDOOWHVWVZLOOEHWZRVLGHGXQOHVVRWKHUZLVHVSHFLILHGLQWKHGHVFULSWLRQRIWKH
DQDO\VHV

%DVHOLQHDQG&KDQJHIURP%DVHOLQH
)RUDOODVVHVVPHQWVUHFRUGHGLQWKLVVWXG\EDVHOLQHLVGHILQHGDVWKHODVWQRQPLVVLQJYDOXH
SULRUWRWKHILUVWGRVHRIVWXG\PHGLFDWLRQVFKHGXOHGRUXQVFKHGXOHG
$Q\DVVHVVPHQWVWDNHQRQWKHVDPHGD\RIILUVWGRVHZLOOEHGHHPHGWRKDYHEHHQFROOHFWHG
SUHGRVHDQGWKHUHIRUHHOLJLEOHWREHVHOHFWHGDVWKHEDVHOLQHYDOXH,IPHDVXUHPHQWIURP9LVLW
LVPLVVLQJ9LVLWRURWKHUXQVFKHGXOHGYLVLWZLOOEHXVHG
&KDQJHIURPEDVHOLQHZLOOEHFDOFXODWHGDVGLIIHUHQFHEHWZHHQWKHYDOXHVPHDVXUHGDWD
VSHFLILFWLPHSRLQWDIWHUEDVHOLQHPLQXVEDVHOLQHYDOXH

5HIHUHQFH6WDUW'DWHDQG6WXG\'D\
6WXG\'D\ZLOOEHFDOFXODWHGIURPWKHUHIHUHQFHVWDUWGDWHDQGZLOOEHXVHGWRVKRZVWDUWVWRS
GD\RIDVVHVVPHQWVDQGHYHQWV
5HIHUHQFHVWDUWGDWHLVGHILQHGDVWKHGD\RIWKHILUVWDGPLQLVWUDWLRQRIWULDOPHGLFDWLRQ'D\
LVWKHGD\RIWKHILUVWLQMHFWLRQRIWULDOPHGLFDWLRQRUIRUVXEMHFWVUDQGRPL]HGEXWQRWWUHDWHG
LWLVWKHGD\RIUDQGRPL]DWLRQDQGZLOODSSHDULQHYHU\OLVWLQJZKHUHDQDVVHVVPHQWGDWHRU
HYHQWGDWHDSSHDUV
,IWKHGDWHRIWKHHYHQWLVRQRUDIWHUWKHUHIHUHQFHGDWHWKHQ


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

x
6WXG\'D\ GDWHRIHYHQW±UHIHUHQFHGDWH
,IWKHGDWHRIWKHHYHQWLVSULRUWRWKHUHIHUHQFHGDWHWKHQ
x
6WXG\'D\ GDWHRIHYHQW±UHIHUHQFHGDWH
,IWKHHYHQWGDWHLVSDUWLDORUPLVVLQJWKHGDWHZLOODSSHDUSDUWLDORUPLVVLQJLQWKHOLVWLQJVDQG
6WXG\'D\DQGDQ\FRUUHVSRQGLQJGXUDWLRQVZLOOEHFDOFXODWHGEDVHGRQWKHDYDLODEOHOHYHORI
GDWD)RULQVWDQFHLIGD\SDUWRIRQHFDOFXODWLRQHOHPHQWLVXQNQRZQWKHQWKHFDOFXODWLRQZLOO
EHFDUULHGRXWRQPRQWKOHYHOXVLQJWKHFRQYHUVLRQRIGD\VPRQWK

5HWHVWV8QVFKHGXOHG9LVLWV(DUO\7HUPLQDWLRQ'DWDDQG5HVFXH9LVLW
,QWKHFDVHRIDUHWHVWDYLVLWVSHFLILFXQVFKHGXOHGDVVHVVPHQWZLOOEHFUHDWHG7KHODWHVW
DYDLODEOHPHDVXUHPHQWZLWKLQWKHSURWRFROVSHFLILHGGD\VYLVLWZLQGRZZLOOEHXVHGIRU
E\YLVLWVXPPDULHV
8QVFKHGXOHGPHDVXUHPHQWVXQOHVVDVVLJQHGWRDSODQQHGYLVLWQXPEHUDVGHVFULEHGLQWKH
SDUDJUDSKDERYHZLOOQRWEHLQFOXGHGLQE\YLVLWWDEOHVXPPDULHVDQGE\YLVLWJUDSKVEXWZLOO
FRQWULEXWHWRWKHODVWREVHUYDWLRQFDUULHGIRUZDUG/2&)YDOXHVGHVFULEHGLQ6$36HFWLRQ
DQGDOVRFRQWULEXWHWREDVHOLQHVHOHFWLRQDVGHVFULEHGLQ6HFWLRQ
6XEMHFWVZKRSUHPDWXUHO\GLVFRQWLQXHWKHVWXG\WUHDWPHQWZLOOFRPSOHWHWKHVDPHDVVHVVPHQWV
DV9LVLW(QGRI7UHDWPHQW9LVLWDQGZLOOQRWEHIXUWKHUIROORZHG(DUO\WHUPLQDWLRQGDWD
ZLOOEHVXPPDUL]HGDQGSUHVHQWHGWRJHWKHUZLWK(QGRI7UHDWPHQW(R79LVLW
5DQGRPL]HGVXEMHFWVZLWKDFHQWUDOODERUDWRU\)DVWLQJ%ORRG*OXFRVH)%*DQG+E$F
YDOXHPHHWLQJWKHFULWHULDIRUODFNRIJO\FDHPLFFRQWUROGXULQJWUHDWPHQWSHULRGPD\EH
HOLJLEOHWRUHFHLYHRSHQODEHOSUHVFULEHGUHVFXHPHGLFDWLRQZKLFKPD\DOORZWKHVXEMHFWWR
UHPDLQLQWKHWULDO5DQGRPL]HGVXEMHFWVZKRPHHWWKHUHSHDWHGUHVFXHFULWHULDVKRXOGEH
VFKHGXOHGIRUDUHVFXHYLVLW6LPLODUWRXQVFKHGXOHGPHDVXUHPHQWVUHVFXHYLVLWUHVXOWVZLOOQRW
EHLQFOXGHGLQE\YLVLWWDEOHVXPPDULHVEXWZLOOFRQWULEXWHWR/2&)DOJRULWKP
/LVWLQJVZLOOLQFOXGHDOOVFKHGXOHGXQVFKHGXOHGUHVFXHYLVLWUHWHVWDQGHDUO\GLVFRQWLQXDWLRQ
GDWDFROOHFWHGLQWKH&5)ZLWKRXWDQ\XQVFKHGXOHGYLVLWZLQGRZPDSSLQJWRVFKHGXOHGYLVLWV

0LVVLQJ'DWD
/2&)ZLOOEHXVHGIRULPSXWDWLRQRIPLVVLQJYDOXHVRIJO\FDHPLFFRQWUROVWDWXV+E$F

/DVWREVHUYDWLRQZLOOEHFDUULHGIRUZDUGDVPDQ\WLPHVDVQHHGHG$OODYDLODEOHGDWD
LQFOXGLQJXQVFKHGXOHGYLVLWVDQGUHVFXHYLVLWVZLOOEHWDNHQLQWRDFFRXQWZKHQLGHQWLI\LQJWKH
ODVWREVHUYDWLRQWREHFDUULHGIRUZDUG


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\


0XOWLFHQWHU6WXG\
6WXG\ZLOOLQFOXGHGDWDIURPDSSUR[LPDWHO\VLWHVLQ.RUHDDOOGDWDZLOOEHSRROHGEHIRUH
DQDO\VLV

0XOWLSOH&RPSDULVRQV0XOWLSOLFLW\
7KHVWDWLVWLFDOVLJQLILFDQFHOHYHOVZLOOQRWEHDGMXVWHGIRUPXOWLSOHK\SRWKHVLVWHVWLQJ
&RQVHTXHQWO\DOOVWDWLVWLFDOWHVWVSHUIRUPHGZLWKVHFRQGDU\VHQVLWLYLW\DQDO\VLVZLOOEH
LQWHUSUHWHGRQO\GHVFULSWLYHO\

'LVSRVLWLRQDQGZLWKGUDZDOV
$OOVXEMHFWVZKRSURYLGHLQIRUPHGFRQVHQWZLOOEHDFFRXQWHGIRULQWKLVVWXG\
7KHIROORZLQJVXEMHFWGLVSRVLWLRQDQGZLWKGUDZDOHYHQWVZLOOEHSUHVHQWHGIRUWKH(15VHW
x ,QIRUPHGFRQVHQWVLJQHG(15
x 6FUHHQIDLOXUHV
x 3DVVHGVFUHHQLQJEXWQRWUDQGRPL]HG
x 5DQGRPL]HG51'
x 5DQGRPL]HGEXWQRWWUHDWHG
x 7UHDWHG6DIHW\$QDO\VLV6HW6$)
x )XOO$QDO\VLV6HW)$6
x 3HU3URWRFRO$QDO\VLV6HW336
x 3UHPDWXUHO\GLVFRQWLQXHGIURPWUHDWPHQWVWXG\
o 3ULPDU\UHDVRQIRUSUHPDWXUHGLVFRQWLQXDWLRQ
x &RPSOHWHGWUHDWPHQWVWXG\
6XEMHFWVYLRODWLQJHDFKLQFOXVLRQDQGH[FOXVLRQFULWHULDZLOORQO\EHOLVWHGIRUWKH(15VHW

'HPRJUDSKLFVDQG2WKHU%DVHOLQH&KDUDFWHULVWLFV
1RVWDWLVWLFDOWHVWLQJZLOOEHFDUULHGRXWIRUGHPRJUDSKLFRURWKHUEDVHOLQHFKDUDFWHULVWLFV
7KHIROORZLQJGHPRJUDSKLFFKDUDFWHULVWLFVZLOOEHSUHVHQWHGIRU6$)
x $JH\HDUV&DOFXODWHGUHODWLYHWRGDWHRI,&)
x *HQGHU
o 0DOH
o )HPDOH


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

 3RVWPHQRSDXVDO
 1RQPHQRSDXVDO
x 3UHJQDQF\WHVWSRVLWLYH
x 3UHJQDQF\WHVWQHJDWLYH
x 3UHJQDQF\WHVWQRWSHUIRUPHG
x (WKQLFLW\
o .RUHDQ
o 2WKHU
x 6XEMHFW([SHULHQFHG7\SH'LDEHWHV
o $FWLYH
o &XUHG
x 7LPHVLQFH7\SH'LDEHWHVGLDJQRVLV\HDUV&DOFXODWHGUHODWLYHWRGDWHRI,&)
7KHIROORZLQJEDVHOLQHFKDUDFWHULVWLFVZLOOEHSUHVHQWHGIRU)$6
x %DVHOLQHWRWDOERG\IDWPDVVJ
x %DVHOLQHWRWDOERG\OHDQPDVVJ
x %DVHOLQHWRWDOERG\IDWSHUFHQWDJH
x %DVHOLQH+E$FOHYHO
x %DVHOLQHIDVWLQJEORRGJOXFRVHOHYHOPJG/
x %DVHOLQHERG\ZHLJKWNJ
x %DVHOLQHZDLVWFLUFXPIHUHQFHFP
x %DVHOLQH%0,NJP
x %DVHOLQH6%3PP+J
x %DVHOLQH'%3PP+J
x %DVHOLQH9$76$7UDWLR
x 9$7DQG6$7DUHD
x %DVHOLQHKV&53PJ/
x %DVHOLQH$GLSRQHFWLRQQJP/
'HILQLWLRQRIEDVHOLQHLVGLVFXVVHGLQ6$36HFWLRQ


'HULYDWLRQV
x $JH<HDUVZLOOEHFDOFXODWHGUHODWLYHWRWKHGDWHRILQIRUPHGFRQVHQW


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

o $JH<HDUV 'DWHRI,QIRUPHG&RQVHQW6LJQHG±'DWHRI%LUWK
x 7LPHVLQFH7\SH'LDEHWHVGLDJQRVLV\HDUV 'DWHRI,QIRUPHG&RQVHQW6LJQHG±
'DWHRIILUVWGLDJQRVLVRI7\SH'LDEHWHV
x %0,NJP :HLJKWNJ+HLJKWP

6XUJLFDO+LVWRU\0HGLFDO+LVWRU\DQG&RQFRPLWDQW3URFHGXUHV
6XUJLFDODQGPHGLFDOKLVWRU\ZLOOEHFROOHFWHGRQ&5)SDJH³S0+´ZKLOVWFRQFRPLWDQW
SURFHGXUHVZLOOEHFROOHFWHGRQ&5)SDJH³S&3´&DSWXUHGGDWDZLOOEHSUHVHQWHGIRU6$)
SRSXODWLRQ
&ROOHFWHGUHFRUGVZLOOEHFRGHGXVLQJ0HG'5$YHUVLRQRUKLJKHU$OOFRGHGWHUPVZLOO
EHVXPPDUL]HGE\62&DQG376XEMHFWKDYLQJPXOWLSOHUHFRUGVLQRQHFDWHJRU\ZLOOEH
FRXQWHGRQO\RQFH5HFRUGVZLOOEHSUHVHQWHGLQDOSKDEHWLFDORUGHU
$GGLWLRQDOO\IRUFRQFRPLWDQWSURFHGXUHVUHDVRQVIRUSURFHGXUHZLOOEHVXPPDUL]HGDQG
UHVFXHSURFHGXUHVZLOOEHSUHVHQWHGDGGLWLRQDOO\

0HGLFDWLRQV
0HGLFDWLRQVZLOOEHFDSWXUHGRQ&5)SDJH³S&0´
³3ULRU´PHGLFDWLRQVDUHPHGLFDWLRQVZKLFKVWRSSHGSULRUWRWKHILUVWGRVHRIVWXG\PHGLFDWLRQ
$OORWKHUPHGLFDWLRQVZLOOEHFRQVLGHUHGFRQFRPLWDQW,QWKHFDVHZKHUHLWLVQRWSRVVLEOHWR
GHILQHDPHGLFDWLRQDVSULRURUFRQFRPLWDQWWKHPHGLFDWLRQZLOOEHFODVVLILHGE\WKHZRUVW
FDVHFRQFRPLWDQW
$OOFRQFRPLWDQWPHGLFDWLRQVLQFOXGLQJUHVFXHPHGLFDWLRQVZLOOEHVXPPDUL]HGIRU6$)VHW
$OOFRQFRPLWDQWPHGLFDWLRQVZLOOEHFRGHGXVLQJ$='UXJ'LFWLRQDU\$=''9HUVLRQ
WRLGHQWLI\WKHLU$QDWRPLFDO7KHUDSHXWLF&KHPLFDO$7&FODVVLILFDWLRQFRGHDQGJHQHULF
WHUP0XOWLSOHGUXJXVDJHE\DSDWLHQWZLOOEHFRXQWHGRQO\RQFHIRUHDFKWKHUDSHXWLFFODVV
5HFRUGVZLOOEHSUHVHQWHGLQDOSKDEHWLFDORUGHU
5HVFXHPHGLFDWLRQZLOOEHVXPPDUL]HGDGGLWLRQDOO\

6WXG\7UHDWPHQW([SRVXUHDQG&RPSOLDQFH
7KHLQYHVWLJDWLRQDOSURGXFW'DSDJOLIOR]LQRU*OLPHSLULGHDQGDGGLWLRQDOGUXJ0HWIRUPLQ
PJZLOOEHWDNHQRUDOO\
%DVHGRQUDQGRPL]DWLRQUHVXOWVVXEMHFWZLOOUHFHLYHHLWKHU*OREDO5HWHQWLRQDQG'LVSRVDO
6WDQGDUG
x 'DSDJOLIOR]LQWDEOHWVPJDGPLQLVWHUHGRUDOO\RQFHGDLO\DVDGGRQWR0HWIRUPLQ
PJRU


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

x *OLPHSLULGHWDEOHWVPJDGPLQLVWHUHGRUDOO\RUWDEOHWVDVDGGRQWR0HWIRUPLQ
PJ*OLPHSLULGHDGPLQLVWUDWLRQFDQEHXSWLWUDWHGWRPJGD\*OLPHSLULGH
GRVHFDQEHGRZQWLWUDWHGWRDQRQ]HUROHYHODWDQ\WLPHWRSUHYHQWK\SRJO\FHPLD
%DVHGRQGUXJDGPLQLVWUDWLRQUHFRUGVWUHDWPHQWFRPSOLDQFHZLOOEHFDOFXODWHGIRUHDFK
VXEMHFW$VXEMHFWZLOOEHFRQVLGHUHGFRPSOLDQWLIPRUHWKDQDQGOHVVWKDQERWK
HQGVLQFOXVLYHRIWKHSODQQHGVWXG\PHGLFDWLRQKDVEHHQWDNHQGXULQJWKHVWXG\SKDVH
5HOHYDQWLQIRUPDWLRQLVFDSWXUHGLQ&5)SDJH³S'$5'´³S'$5*´³S'$50´DQG
³S'$5295´
)RU6$)VHWIROORZLQJVWDWLVWLFVZLOOEHSUHVHQWHGDQGOLVWHGIRUHDFKVXEMHFW
x $FWXDOGXUDWLRQRIH[SRVXUHGD\V
x 'XUDWLRQRILQWHUUXSWLRQVGD\V
x &XPXODWLYHGRVHPJ
x $FWXDOGRVHLQWHQVLW\PJGD\
x 7RWDOSODQQHGGRVHPJIRUVXEMHFWVUHFHLYLQJ*OLPHSLULGHRQO\
x &RPSOLDQFH
x &RPSOLDQFHFDWHJRU\
x ,QFLGHQFHRIVWXG\PHGLFDWLRQRYHUGRVH
x ,QFLGHQFHRIGRVHDGMXVWPHQW
x 7\SHRIGRVHDGMXVWPHQW
x 5HDVRQVIRUGRVHDGMXVWPHQW
x 1XPEHURIGRVHDGMXVWPHQWVSHUVXEMHFW
1RWHWKDWGRVHDGMXVWPHQWRQO\UHIHUVWRDFWXDOGRVDJHFKDQJH$GMXVWPHQWLQSUHVFULEHG
DPRXQWRI*OLPHSLULGHZKLFKGRHVQRWOHDGWRDFWXDOGRVHFKDQJHZLOOQRWEHFRQVLGHUHGD
GRVHDGMXVWPHQW
)RU0HWIRUPLQH[SRVXUHVWDWXVRQO\IROORZLQJVXPPDULHVZLOOEHSUHVHQWHG
x $FWXDOGXUDWLRQRIH[SRVXUHGD\V
x 'XUDWLRQRILQWHUUXSWLRQVGD\V
x &XPXODWLYHGRVHPJ
x $FWXDOGRVHLQWHQVLW\PJGD\


'HULYDWLRQV
x $FWXDOGXUDWLRQRIH[SRVXUHGD\V VWRSGDWHRIDGPLQLVWUDWLRQ±VWDUWGDWHRI
DGPLQLVWUDWLRQ


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

x 'XUDWLRQRILQWHUUXSWLRQVGD\V 6XPRIVWRSGDWHRIHDFKLQWHUUXSWLRQ±VWDUWGDWHRI
HDFKLQWHUUXSWLRQ
o )RU0HWIRUPLQLI0HWIRUPLQFRQVXPSWLRQVWRSVEHIRUHVWXG\PHGLFDWLRQ
GXUDWLRQEHWZHHQ0HWIRUPLQWHUPLQDWLRQDQGHQGRIVWXG\WUHDWPHQWZLOOEH
FRQVLGHUHG0HWIRUPLQLQWHUUXSWLRQ
x $FWXDOGRVHLQWHQVLW\PJGD\ &XPXODWLYHGRVHPJ$FWXDOGXUDWLRQRIH[SRVXUH
GD\V
x 7RWDOSODQQHGGRVHPJRIVXEMHFWVUHFHLYLQJ*OLPHSLULGH 
σ
ሺ݌ݎ݁ݏܿݎܾ݅݁݀݀݋ݏ݁݈݁ݒ݈݁ܽݐ݌݁ݎ݅݋݀݅ሻൈሺݏݐ݋݌݀ܽݐ݁݋݂݌݁ݎ݅݋݀݅െ
௔௟௟௜
ݏݐܽݎݐ݀ܽݐ݁݋݂݌݁ݎ݅݋݀݅ሻ
:KHUHHDFKSHULRGUHIHUVWRDWLPHIUDPHZKRVHSUHVFULEHGGRVHOHYHOLVFRQVWDQW
:KHQHYHUWKHSUHVFULEHGGRVHOHYHOLVFKDQJHGDQHZSHULRGVKDOOEHFUHDWHG
x 7RWDO3ODQQHGGRVHPJRIVXEMHFWVUHFHLYLQJ'DSDJOLIOR]LQ PJGD\ൈ$FWXDO
GXUDWLRQRIH[SRVXUHGD\
x &RPSOLDQFHLVEDVHGFXPXODWLYHGRVHDQGWKHWRWDOSODQQHGGRVHDQGZLOOEH
FDOFXODWHGDVIROORZV
&RPSOLDQFH ͳͲͲΨ ൈ


x &RPSOLDQFHZLOOEHIXUWKHUFDWHJRUL]HGLQWROHYHOV
o 
o DQG
o !

3ULPDU\(IILFDF\$QDO\VLV

3ULPDU\(IILFDF\9DULDEOH
7KHSULPDU\HIILFDF\YDULDEOHRIWKHVWXG\LVWKHFKDQJHLQWRWDOERG\IDWPDVVLQJUDPVDQG
SHUFHQWDJHVIURPEDVHOLQHXVLQJ';$VFDQLQZHHNVDIWHUWKHVWDUWRIWKHWUHDWPHQWZKLFK
LVGHILQHGDVWKHWRWDOERG\IDWPDVVDW:HHNVXEWUDFWVWRWDOERG\IDWPDVVDWEDVHOLQH
7RWDOERG\IDWPDVVDQGSHUFHQWDJHVZLOOEHFDSWXUHGRQ&5)SDJH³S';$´DQG³S';$´

3ULPDU\$QDO\VLVRI3ULPDU\(QGSRLQW
7KHWHVWIRUHTXLYDOHQFHEHWZHHQWZRWUHDWPHQWJURXSVZLOOEHSHUIRUPHGIRU)$6SRSXODWLRQ
7KHK\SRWKHVLVWREHWHVWHGDUHJLYHQDV
ܪ଴ǣɊ୘ൌߤ௖ܸ݁ݎݏݑݏܪ஺ǣ ߤ்്ߤ஼
:KHUHɊ୘GHQRWHVWKHPHDQFKDQJHLQWHVWUHVXOWVIURP%DVHOLQHWR:HHNRIVXEMHFWVZKR
UHFHLYHG'DSDJOLIOR]LQ7UHDWPHQWXQGHULQYHVWLJDWLRQ7DQGߤ௖GHQRWHVWKHPHDQFKDQJHLQ
WHVWUHVXOWVIURP%DVHOLQHWR:HHNRIVXEMHFWVZKRUHFHLYHG*OLPHSLULGH&RPSDUDWRU&


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

7KHSULPDU\HIILFDF\YDULDEOHZLOOEHDQDO\VHGXVLQJDQ$1&29$PRGHOZLWKWUHDWPHQW
JURXSDVIDFWRUDQG%DVHOLQHWHVWUHVXOWVDVDFRYDULDWHDVIROORZLQJ
ሺ୧୨ሻൌɊǤǤ ൅ܶݎݐ௜൅ܤܽݏ݈ܻ݁݅݊݁௜௝
:KHUHL M «QL
ሺ୧୨ሻGHQRWHVWKHPHDQFKDQJHLQWRWDOERG\IDWPDVVLQJSHUFHQWDJHVIURPEDVHOLQHWR
ZHHNRIMWKVXEMHFWLQWUHDWPHQWJURXSL
ɊǤǤGHQRWHVWKHRYHUDOOPHDQWRWDOERG\PDVVIURPEDVHOLQHWRZHHN
ܶݎݐ௜GHQRWHVWKHWUHDWPHQWHIIHFWRIHDFKJURXSIURPWKHRYHUDOOPHDQ
ܤܽݏ݈ܻ݁݅݊݁௜௝GHQRWHVWKHEDVHOLQHWRWDOERG\IDWPDVVRIMWKVXEMHFWLQWUHDWPHQWJURXSL
7KHPRGHOZLOOEHXVHGWRGHULYHDOHDVWVTXDUHVHVWLPDWHRIWKHWUHDWPHQWGLIIHUHQFHZLWK
FRUUHVSRQGLQJWZRVLGHGFRQILGHQFHLQWHUYDO&,DQGWZRVLGHG:DOGSYDOXH
)XUWKHUWZRVLGHG&,VIRUWKHSULPDU\HQGSRLQWZLWKLQHDFKWUHDWPHQWJURXSZLOOEH
FDOFXODWHG0RGHOGLDJQRVLVVWDWLVWLFVZLOOEHSUHVHQWHG
)ROORZLQJ6$6FRGHFDQEHXVHGWRREWDLQDERYHVWDWLVWLFV
proc glm data=DD; 
class TRTP; 
model ChgFat=TRTP BaseFat /solution;
lsmeans TRTP/Pdiff=CONTROL('Comparator')cl;
run; quit;
,QRUGHUWRGHVFULSWLYHO\SUHVHQWWKHSULPDU\HQGSRLQWWRWDOERG\IDWPDVVLQJUDPVDQGWRWDO
SHUFHQWRIERG\IDWIURPEDVHOLQHDQG:HHNZLOOEHSUHVHQWHGIRU)$6VHWDQGOLVWHGIRU
6$)VHW&KDQJHIURPEDVHOLQHWR:HHNIRU)$6VXEMHFWVZLOODOVREHVXPPDUL]HG

6HQVLWLYLW\$QDO\VLVRI3ULPDU\(QGSRLQW
7RHYDOXDWHWKHLPSDFWRISURWRFROFRPSOLDQFHRQSULPDU\HIILFDF\HQGSRLQWSULPDU\HIILFDF\
DQDO\VLVPHWKRGZLOOEHUHSHDWHGRQWKH336SRSXODWLRQ
7RHYDOXDWHWKHLPSDFWRIEDVHZHLJKWLQWRWDOERG\IDWPDVVSULPDU\HIILFDF\DQDO\VLVZLOOEH
UHSHDWHGEDVHGRQWRWDOERG\IDWSHUFHQWDJHIRUERWK)$6DQG336
7RHYDOXDWHWKHLPSDFWRIJHQGHUUDWLRRQSULPDU\HIILFDF\HQGSRLQWSULPDU\HIILFDF\DQDO\VLV
PHWKRGZLOOEHSHUIRUPHGXVLQJ$1&29$PRGHOZLWKWUHDWPHQWJURXSDVIDFWRUDQG%DVHOLQH
WHVWUHVXOWVDQGJHQGHUDVDFRYDULDWHRQ)$6DQG33SRSXODWLRQDVIROORZLQJ
ሺ୧୨ሻൌɊǤǤ ൅ܶݎݐ௜൅ܤܽݏ݈ܻ݁݅݊݁௜௝൅ܩ݁݊݀݁ݎܼ݆݅
:KHUHL M «QL
ሺ୧୨ሻGHQRWHVWKHPHDQFKDQJHLQWRWDOERG\IDWPDVVLQJRUIURPEDVHOLQHWRZHHNRI
MWKVXEMHFWLQWUHDWPHQWJURXSL
ɊǤǤGHQRWHVWKHRYHUDOOPHDQWRWDOERG\PDVVLQJRUIURPEDVHOLQHWRZHHN


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

ܶݎݐ௜GHQRWHVWKHWUHDWPHQWHIIHFWRIHDFKJURXSIURPWKHRYHUDOOPHDQ
ܤܽݏ݈ܻ݁݅݊݁௜௝GHQRWHVWKHEDVHOLQHWRWDOERG\IDWPDVVRIMWKVXEMHFWLQWUHDWPHQWJURXSL
ܩ݁݊݀݁ݎܼ݆݅GHQRWHVWKHJHQGHURIMWKVXEMHFWLQWUHDWPHQWJURXSL
7KHPRGHOZLOOEHXVHGWRGHULYHDOHDVWVTXDUHVHVWLPDWHRIWKHWUHDWPHQWGLIIHUHQFHZLWK
FRUUHVSRQGLQJWZRVLGHGFRQILGHQFHLQWHUYDO&,DQGWZRVLGHG:DOGSYDOXH
)XUWKHUWZRVLGHG&,VIRUWKHSULPDU\HQGSRLQWZLWKLQHDFKWUHDWPHQWJURXSZLOOEH
FDOFXODWHG0RGHOGLDJQRVLVVWDWLVWLFVZLOOEHSUHVHQWHG
)ROORZLQJ6$6FRGHFDQEHXVHGWRREWDLQDERYHVWDWLVWLFV
proc glm data=DD; 
class TRTP gender; 
model ChgFat=TRTP BaseFat gender/solution;
lsmeans TRTP/Pdiff=CONTROL('Comparator')cl;
run; quit;

6HFRQGDU\(IILFDF\$QDO\VHV
7KHVHFRQGDU\HIILFDF\DQDO\VHVZLOOEHSHUIRUPHGIRUWKH)$6RQO\)RUHDFKYDULDEOHWKH
WHVWIRUHTXLYDOHQFHEHWZHHQWZRWUHDWPHQWJURXSVZLOOEHFDUULHGRXWZLWKWKHIROORZLQJ
VSHFLILHGVWDWLVWLFDOPHWKRGV

6HFRQGDU\(IILFDF\9DULDEOHV
7KHUHDUHPXOWLSOHVHFRQGDU\HIILFDF\YDULDEOHVRILQWHUHVWDVIROORZLQJ
7KHFKDQJHLQ+E$FOHYHOVIURPEDVHOLQHWRZHHNVZKLFKLVGHILQHGDVWKH+E$FOHYHO
PHDVXUHGDW:HHNDQGZHHNVVXEWUDFWVWKHVXEMHFW¶VEDVHOLQHYDOXH
7KHSURSRUWLRQRIVXEMHFWVDFKLHYLQJDJO\FHPLFUHVSRQVHGHILQHGDV+E$FDW:HHN

7KHFKDQJHLQ)%6OHYHOVIURPEDVHOLQHWRZHHNVZKLFKLVGHILQHGDVWKH)%6OHYHO
PHDVXUHGDW:HHNDQGZHHNVVXEWUDFWWKHVXEMHFW¶VEDVHOLQHYDOXH
7KHFKDQJHVLQERG\ZHLJKWZDLVWFLUFXPIHUHQFH%0,IURPEDVHOLQHWRDQG
ZHHNVZKLFKLVGHILQHGDVWKHFRUUHVSRQGLQJUHVXOWVPHDVXUHGDW:HHN
DQGVXEWUDFWWKHVXEMHFW¶VEDVHOLQHYDOXH
7KHFKDQJHVLQ6%3DQG'%3IURPEDVHOLQHWRDQGZHHNVZKLFKLV
GHILQHGDVWKHUHVXOWVPHDVXUHGDW:HHNDQGZHHNVVXEWUDFWWKHVXEMHFW¶V
EDVHOLQHYDOXH
7KHFKDQJHVLQDEGRPLQDO9$7DQG6$7DUHD9$76$7UDWLRXVLQJDEGRPLQDO&7IURP
EDVHOLQHWRZHHNVZKLFKLVGHILQHGDVWKHUHVXOWVPHDVXUHGDW:HHNVXEWUDFWWKH
VXEMHFW¶VEDVHOLQHYDOXH


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

7KHFKDQJHVLQOHDQPDVVXVLQJ'XDO(QHUJ\;UD\$EVRUSWLRPHWU\';$IURPEDVHOLQHWR
ZHHNVZKLFKLVGHILQHGDVWKHUHVXOWVPHDVXUHGDW:HHNVXEWUDFWWKHVXEMHFW¶VEDVHOLQH
YDOXH
7KHFKDQJHVLQKLJKVHQVLWLYLW\&53KV&53DQGDGLSRQHFWLQIURPEDVHOLQHWRZHHNV
ZKLFKLVGHILQHGDVWKHUHVXOWVPHDVXUHGDW:HHNVXEWUDFWWKHVXEMHFW¶VEDVHOLQHYDOXH

3ULPDU\$QDO\VLVRI6HFRQGDU\(QGSRLQWV
7RHYDOXDWHWKHGLIIHUHQFHEHWZHHQWZRWUHDWPHQWJURXSVUHJDUGLQJFKDQJHLQ+E$FOHYHOV
IURPEDVHOLQHWRZHHNVDQGZHHNVWKHIROORZLQJK\SRWKHVLVZLOOEHWHVWHG
ܪ଴ǣɊ୘ൌߤ௖ܸ݁ݎݏݑݏܪ஺ǣ ߤ்്ߤ஼
:KHUHɊ୘GHQRWHVWKHPHDQFKDQJHLQWHVWUHVXOWVIURP%DVHOLQHWR:HHNRIVXEMHFWV
UHFHLYHG'DSDJOLIOR]LQ7UHDWPHQWXQGHULQYHVWLJDWLRQ7DQGߤ௖GHQRWHVWKHPHDQFKDQJHLQ
WHVWUHVXOWVIURP%DVHOLQHWR:HHNDQGZHHNVRIVXEMHFWVUHFHLYHG
*OLPHSLULGH&RPSDUDWRU&
7KHVHFRQGDU\YDULDEOHZLOOEHDQDO\VHGXVLQJD0L[HGHIIHFW0RGHO5HSHDW0HDVXUHPHQW
0050PRGHOZLWKWUHDWPHQWJURXSYLVLWYLVLWWUHDWPHQWJURXSDQGEDVHOLQHPHDVXUHPHQW
DVIDFWRUVDVIROORZLQJ
ሺ୧୨୩ሻൌȾ଴൅ߚଵܶݎݐ௜൅ߚଶܸ௝൅ߚଷܶݎݐ௜ൈܸ௝൅ߚସܤܽݏ݁௜௞
:KHUHL M «N «QL
ሺ୧୨୩ሻGHQRWHVWKHFKDQJHLQWHVWUHVXOWIURPEDVHOLQHWRWKHMWKYLVLWSRVWEDVHOLQHRIWKHNWK
VXEMHFWLQWUHDWPHQWJURXSL
ܶݎݐ௜GHQRWHVWKHWUHDWPHQWHIIHFWRIHDFKJURXS
9MGHQRWHVWKHMWKYLVLWSRVWEDVHOLQH
ܶݎݐ௜ൈܸ௝GHQRWHVWKHLQWHUDFWLRQWHUPRIWUHDWPHQWJURXSDQGYLVLW 
ܤܽݏ݁௜௞GHQRWHVWKHEDVHOLQHWHVWUHVXOWRINWKVXEMHFWLQWUHDWPHQWJURXSL
7KHDERYHPRGHOZLOOEHDSSOLHGWRDQDO\VHWKHVHFRQGDU\HIILFDF\HQGSRLQWV$OOQRQPLVVLQJ
YLVLWGDWDZLOOEHXVHG7KHPRGHOZLOOEHXVHGWRGHULYHDOHDVWVTXDUHVHVWLPDWHRIWKH
WUHDWPHQWGLIIHUHQFHZLWKD&,DQGFRUUHVSRQGLQJ:DOGWZRVLGHGSYDOXH0LVVLQJGDWD
ZLOOQRWEHLPSXWHG
7KHIROORZLQJ6$6FRGHFDQEHXVHGWRREWDLQWKHDERYHVWDWLVWLFV
proc mixed data=DATA; where AVISITN in (X,X,X,X) and 
PARAMCD="XXX";
class TRTP AVISIT USUBJID; 
model AVAL=TRTP | AVISIT  Base/solution;
repeated AVISIT/type=un subject=usubjid r rcorr;
lsmeans TRTP*AVISIT/diff=CONTROL('Comparator' 'Week52') cl;


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

run;
,QRUGHUWRGHVFULSWLYHO\SUHVHQWWKH+E$FGDWDPHDVXUHPHQWUHVXOWVIURPEDVHOLQHDQGHDFK
VFKHGXOHGSRVWEDVHOLQHYLVLWZLOOEHSUHVHQWHGIRU)$6VHW5HVXOWVZLOOEHOLVWHGIRU6$)VHW
&KDQJHIURPEDVHOLQHIRU)$6VXEMHFWVZLOODOVREHVXPPDUL]HGIRUDOOVFKHGXOHGSRVW
EDVHOLQHYLVLWV

7RHYDOXDWHWKHSURSRUWLRQRIVXEMHFWVDFKLHYLQJDJO\FHPLFUHVSRQVHGHILQHGDV+E$F
DW:HHNIROORZLQJK\SRWKHVLVZLOOEHWHVWHG
ܪ଴ǣɎ୘ൌߨ௖ܸ݁ݎݏݑݏܪ஺ǣ ߨ்്ߨ஼
,QWKLVVHFRQGDU\DQDO\VLVWKHVXFFHVVIXOHYHQWLVWRDFKLHYHDQ+E$FDW:HHN,Q
DERYHK\SRWKHVLVɎ୘GHQRWHVWKHSUREDELOLW\RIVXFFHVVIRUVXEMHFWVUHFHLYHG'DSDJOLIOR]LQ
7UHDWPHQWXQGHULQYHVWLJDWLRQ7DQGߨ஼GHQRWHVWKHSUREDELOLW\RIVXFFHVVIRUVXEMHFWV
UHFHLYHG*OLPHSLULGH&RPSDUDWRU&7RREWDLQDFRPSOHWHGDWDVWUXFWXUHPLVVLQJGDWDZLOO
EHLPSXWHGXVLQJ/2&)
7KHVHFRQGDU\YDULDEOHZLOOEHDQDO\VHGXVLQJD/RJLVWLF5HJUHVVLRQPRGHOZLWKWUHDWPHQW
JURXSDQGEDVHOLQHPHDVXUHPHQWDVIDFWRUDVIROORZLQJ
ܮ݋݃݅ݐሺܧሺܲ௜௝ሻሻൌȾ଴൅ߚଵܶݎݐ௜൅ߚଶܤܽݏ݁௜௝
:KHUHL M «QL
ܮ݋݃݅ݐሺܧሺܲ௜௝ሻሻGHQRWHVWKHORJLWORJRGGVRIWKHH[SHFWHGSUREDELOLW\RIVXFFHVVDW:HHN
IRUWKHMWKVXEMHFWLQWUHDWPHQWJURXSL
ܶݎݐ௜GHQRWHVWKHWUHDWPHQWHIIHFWRIHDFKJURXS
ܤܽݏ݁௜௝GHQRWHVWKHEDVHOLQHQXPHULFWHVWUHVXOWLQWKLVFDVHEDVHOLQH+E$FOHYHORIMWK
VXEMHFWLQWUHDWPHQWJURXSL
$ERYHPRGHOZLOOEHDSSOLHGWRDQDO\VHWKHVHFRQGDU\HIILFDF\HQGSRLQW7KHPRGHOZLOOEH
XVHGWRGHULYHDQHVWLPDWHGRGGVUDWLREHWZHHQWZRWUHDWPHQWJURXSVWUHDWPHQWYHUVXV
FRPSDUDWRUWRJHWKHUZLWKDFRQILGHQFHLQWHUYDODQGFRUUHVSRQGLQJ:DOGWZRVLGHGS
YDOXH
)ROORZLQJ6$6FRGHFDQEHXVHGWRREWDLQDERYHVWDWLVWLFV
proc logistic data=Data descending;
class AVALC(ref='N') TRTP (ref='Comparator')/param=glm; 
model AVALC (ref='N')= TRTP Base/link=logit;  
lsmeans TRTP/e diff=CONTROL('Comparator') cl oddsratio;
run;
,QRUGHUWRGHVFULSWLYHO\SUHVHQWWKH+E$FFODVVHVPHDVXUHPHQWUHVXOWVSURSRUWLRQRI
VXEMHFWVKDYLQJ+E$FIURPEDVHOLQHZLOOEHSUHVHQWHGIRU)$6VHW5HVXOWVZLOOEH
OLVWHGIRU6$)VHW


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\


7RHYDOXDWHWKHFKDQJHLQ)%6OHYHOVIURPEDVHOLQHWRZHHNVDQGZHHNV
ZKLFKLVGHILQHGDVWKH)%6OHYHOPHDVXUHGDW:HHNDQGZHHNVVXEWUDFW
WKHVXEMHFW¶VEDVHOLQHYDOXH
7KHVWDWLVWLFDOPRGHOOLQJDQGDQDO\VLVZLOOEHSHUIRUPHGLQWKHVDPHPDQQHUDVVHFRQGDU\
HIILFDF\YDULDEOH+E$FOHYHOXVLQJD0050PRGHO
,QRUGHUWRGHVFULSWLYHO\SUHVHQWWKH)%6OHYHOVPHDVXUHPHQWUHVXOWVIURPEDVHOLQHDQGHDFK
VFKHGXOHGSRVWEDVHOLQHYLVLWZLOOEHSUHVHQWHGIRU)$6VHW5HVXOWVZLOOEHOLVWHGIRU6$)VHW
&KDQJHIURPEDVHOLQHIRU)$6VXEMHFWVZLOODOVREHVXPPDUL]HGIRUDOOVFKHGXOHGSRVW
EDVHOLQHYLVLWV

7RHYDOXDWHWKHFKDQJHVLQERG\ZHLJKWZDLVWFLUFXPIHUHQFH%0,IURPEDVHOLQHWRZHHNV
DQGZKLFKLVGHILQHGDVWKHFRUUHVSRQGLQJUHVXOWVPHDVXUHGDW:HHN
DQGVXEWUDFWWKHVXEMHFW¶VEDVHOLQHYDOXH
7KHVWDWLVWLFDOPRGHOOLQJDQGDQDO\VLVZLOOEHSHUIRUPHGLQWKHVDPHPDQQHUDVVHFRQGDU\
HIILFDF\YDULDEOH+E$FOHYHOXVLQJD0050PRGHO
'HVFULSWLYHSUHVHQWDWLRQRIERG\ZHLJKWZDLVWFLUFXPIHUHQFHDQG%0,ZLOOEHSUHSDUHG
WRJHWKHUZLWKRWKHUYLWDOVLJQVLQ)$6VHW

7RHYDOXDWHWKHFKDQJHVLQ6%3DQG'%3IURPEDVHOLQHWRDQGZHHNV
ZKLFKLVGHILQHGDVWKHUHVXOWVPHDVXUHGDW:HHNDQGZHHNVVXEWUDFWWKH
VXEMHFW¶VEDVHOLQHYDOXH
7KHVWDWLVWLFDOPRGHOOLQJDQGDQDO\VLVZLOOEHSHUIRUPHGLQWKHVDPHPDQQHUDVVHFRQGDU\
HIILFDF\YDULDEOH+E$FOHYHOXVLQJD0050PRGHO
'HVFULSWLYHSUHVHQWDWLRQRIEORRGSUHVVXUHZLOOEHSUHSDUHGIRU)$6VHWDQGWRJHWKHUZLWK
RWKHUYLWDOVLJQVLQ6$)VHW5HVXOWVZLOOEHOLVWHGIRU6$)VHW

7RHYDOXDWHWKHFKDQJHVLQDEGRPLQDO9$7DQG6$7DUHD9$76$7UDWLRXVLQJDEGRPLQDO
&7IURPEDVHOLQHWRZHHNVZKLFKLVGHILQHGDVWKHUHVXOWVPHDVXUHGDW:HHNVXEWUDFW
WKHVXEMHFW¶VEDVHOLQHYDOXH
7KHVWDWLVWLFDOPRGHOOLQJDQGDQDO\VLVZLOOEHSHUIRUPHGLQWKHVDPHPDQQHUDVWKHSULPDU\
HIILFDF\YDULDEOHXVLQJDQ$1&29$PRGHO


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

,QRUGHUWRGHVFULSWLYHO\SUHVHQWWKH9$7DQG6$7OHYHOVPHDVXUHPHQWUHVXOWV9$76$7
DQG9$76$7UDWLRIURPEDVHOLQHDQG:HHNZLOOEHSUHVHQWHGIRU)$6VHW5HVXOWVZLOO
EHOLVWHGIRU6$)VHW&KDQJHIURPEDVHOLQHWR:HHNIRU)$6VXEMHFWVZLOODOVREH
VXPPDUL]HG
7RHYDOXDWHWKHFKDQJHVLQOHDQPDVVXVLQJ'XDO(QHUJ\;UD\$EVRUSWLRPHWU\';$IURP
EDVHOLQHWRZHHNVZKLFKLVGHILQHGDVWKHUHVXOWVPHDVXUHGDW:HHNVXEWUDFWWKH
VXEMHFW¶VEDVHOLQHYDOXH
7KHVWDWLVWLFDOPRGHOOLQJDQGDQDO\VLVZLOOEHSHUIRUPHGLQWKHVDPHPDQQHUDVWKHSULPDU\
HIILFDF\YDULDEOHXVLQJDQ$1&29$PRGHO
,QRUGHUWRGHVFULSWLYHO\SUHVHQWWKHOHDQPDVVIURPEDVHOLQHDQG:HHNZLOOEHSUHVHQWHG
IRU)$6VHW5HVXOWVZLOOEHOLVWHGIRU6$)VHW&KDQJHIURPEDVHOLQHWR:HHNIRU)$6
VXEMHFWVZLOODOVREHVXPPDUL]HG

7RHYDOXDWHWKHFKDQJHVLQKLJKVHQVLWLYLW\&53KV&53DQGDGLSRQHFWLQIURPEDVHOLQHWR
ZHHNVZKLFKLVGHILQHGDVWKHUHVXOWVPHDVXUHGDW:HHNVXEWUDFWWKHVXEMHFW¶VEDVHOLQH
YDOXH
7KHVWDWLVWLFDOPRGHOOLQJDQGDQDO\VLVZLOOEHSHUIRUPHGLQWKHVDPHPDQQHUDVWKHSULPDU\
HIILFDF\YDULDEOHXVLQJDQ$1&29$PRGHO
,QRUGHUWRGHVFULSWLYHO\SUHVHQWWKHKV&53DQGDGLSRQHFWLQOHYHOVPHDVXUHPHQWUHVXOWVIURP
EDVHOLQHDQG:HHNZLOOEHSUHVHQWHGIRU)$6VHW5HVXOWVZLOOEHOLVWHGIRU6$)VHW
&KDQJHIURPEDVHOLQHWR:HHNIRU)$6VXEMHFWVZLOODOVREHVXPPDUL]HG


6HQVLWLYLW\$QDO\VLVRI6HFRQGDU\(QGSRLQWV
7RDVVHVVWKHUREXVWQHVVRIWKHPLVVLQJGDWDLPSXWDWLRQ/2&)WKHVDPHPRGHODQGVWDWLVWLFV
ZLOOEHJHQHUDWHGIRU)$6SRSXODWLRQZLWKRQO\WUXO\REVHUYHGGDWDZKHQHYDOXDWLQJ
SURSRUWLRQRIVXEMHFWVDFKLHYLQJDJO\FHPLFUHVSRQVH
7RHYDOXDWHWKHLPSDFWRISURWRFROFRPSOLDQFHRQVHFRQGDU\HIILFDF\HQGSRLQWVHFRQGDU\
HIILFDF\PRGHOVZLWKLPSXWHGGDWDIRUJO\FHPLFUHVSRQVHPHWKRGZLOOEHUHSHDWHGRQWKH
336SRSXODWLRQ
7RHYDOXDWHWKHLPSDFWRIJHQGHUUDWLRRQVHFRQGDU\HIILFDF\HQGSRLQWVWKHVHFRQGDU\
HQGSRLQWVZLOOEHDQDO\]HGDVDVHQVLWLYLW\DQDO\VLVE\DPL[HGPRGHOIRUUHSHDWHGPHDVXUHV
0050ZKHUHDOOSRVWEDVHOLQHVHFRQGDU\HQGSRLQWV+E$FOHYHOV)%6OHYHOVERG\
ZHLJKWZDLVWFLUFXPIHUHQFH%0,6%3DQG'%3REWDLQHGDWDOOSODQQHGYLVLWVEHIRUH
GLVFRQWLQXDWLRQIURPUDQGRPL]HGWUHDWPHQWDQGYLVLWDQGWUHDWPHQWDUHLQFOXGHGDVIL[HG
IDFWRUVDQG%DVHOLQHVHFRQGDU\HQGSRLQWVDQGJHQGHUDVFRYDULDWHV)XUWKHUPRUHLQWHUDFWLRQ
WHUPVRIYLVLWE\WUHDWPHQWYLVLWE\JHQGHUDQGYLVLWE\UHVSHFWLYH%DVHOLQHVHFRQGDU\


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

HQGSRLQWVZLOOEHLQFOXGHG$QXQVWUXFWXUHGFRYDULDQFHPDWUL[IRUUHVSHFWLYH%DVHOLQH
VHFRQGDU\HQGSRLQWPHDVXUHPHQWVZLWKLQVDPHSDWLHQWZLOOEHHPSOR\HG5HJDUGLQJPLVVLQJ
GDWDWKLVDQDO\VLVDSSURDFKUHOLHVRQWKHDVVXPSWLRQWKDWGDWDDUHPLVVLQJDWUDQGRP7KH
HVWLPDWHGGLIIHUHQFHVEHWZHHQHDFKWUHDWPHQWJURXSVDW:HHNDQGFRUUHVSRQGLQJWZRVLGHG
SYDOXHVDQG&,ZLOOEHSUHVHQWHG
7RHYDOXDWHWKHLPSDFWRIJHQGHUUDWLRRQVHFRQGDU\HIILFDF\HQGSRLQW9$76$7DUHD
9$76$7UDWLRDQGWRWDOERG\OHDQPDVVWKHVHSDUDPHWHUVZLOOEHDQDO\VHGXVLQJ$1&29$
PRGHOZLWKWUHDWPHQWJURXSDVIDFWRUDQG%DVHOLQHWHVWUHVXOWVDQGJHQGHUDVDFRYDULDWHRQ
)$6DQG336SRSXODWLRQ7KHVWDWLVWLFDOPRGHOOLQJDQGDQDO\VLVZLOOEHSHUIRUPHGLQWKHVDPH
PDQQHUDVWKHSULPDU\HIILFDF\YDULDEOHXVLQJDQ$1&29$PRGHO6HQVLWLYLW\$QDO\VLV


6DIHW\$QDO\VHV
$OOVDIHW\DQDO\VHVZLOOEHSHUIRUPHGEDVHGRQ6$)VHW7KHUHZLOOEHQRVWDWLVWLFDO
FRPSDULVRQEHWZHHQWUHDWPHQWJURXSVIRUVDIHW\GDWDH[FHSWK\SRJO\FHPLFHYHQWV
$OOVXEVHFWLRQVEHORZZLOOEHOLVWHGIRU6$)VHW

$GYHUVH(YHQWV$(V
$QDGYHUVHHYHQWLVWKHGHYHORSPHQWRIDQXQGHVLUDEOHPHGLFDOFRQGLWLRQRUWKHGHWHULRUDWLRQ
RIDSUHH[LVWLQJPHGLFDOFRQGLWLRQIROORZLQJRUGXULQJH[SRVXUHWRDSKDUPDFHXWLFDOSURGXFW
ZKHWKHURUQRWFRQVLGHUHGFDXVDOO\UHODWHGWRWKHSURGXFW
$(VZLOOEHFROOHFWHGRQ&5)IRUP³S$(´IURPWKHILUVWGRVLQJGD\WR(27YLVLWDQGDOO
UHFRUGHG$(VZLOOEHUHSRUWHGLQWDEOHVDQGOLVWLQJV
$GYHUVH(YHQWV$(VZLOOEHFRGHGXVLQJWKH0HG'5$FHQWUDOFRGLQJGLFWLRQDU\9HUVLRQ
7KHWHUPVQRW\HWFRGHGLQWKHGDWDPDQDJHPHQWWUDQVIHUZLOOEHVXPPDUL]HGLQWKH
µ8QFRGHG¶FDWHJRU\
3UHH[LVWLQJFRQGLWLRQVZLOOEHUHFRUGHGDWEDVHOLQHRQ0HGLFDO+LVWRU\SDJHRI&5),IDSUH
H[LVWLQJFRQGLWLRQFKDQJHVLQVHYHULW\LWZLOOEHUHSRUWHGDVDQ$(,IDSHUVLVWHQW$(EHFRPHV
PRUHVHYHUHLWVKRXOGEHUHFRUGHGDJDLQZLWKWKHXSGDWHGVHYHULW\
$QRYHUDOOVXPPDU\RIQXPEHURISDWLHQWVZLWKLQHDFKRIWKHFDWHJRULHVGHVFULEHGLQWKHVXE
VHFWLRQEHORZZLOOEHSURYLGHGDVVSHFLILHGLQWKHRXWSXWWHPSODWHV7KHIRFXVRIDGYHUVH
HYHQWUHSRUWLQJLQUHVXOWWDEOHVZLOOEHEDVHGRQ7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV
7($(V
,QFLGHQFHRI$(VZLOOEHSUHVHQWHGE\6\VWHP2UJDQ&ODVV62&DQG3UHIHUUHG7HUP37
DQGDOVREURNHQGRZQE\PD[LPXPLQWHQVLW\DQGUHODWLRQVKLSWRVWXG\PHGLFDWLRQ,QWKHFDVH
WKDWDSDWLHQWUHSRUWVPXOWLSOH$(VZLWKLQWKHVDPHFDWHJRU\WKH$(ZLWKZRUVWVHYHULW\DQG
VWURQJHVWUHODWLRQVKLSZLOOEHXVHGLQWKHFRUUHVSRQGLQJVXPPDULHV


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\


,QWHQVLW\
7KHSDWLHQWSDUHQWVOHJDOJXDUGLDQVZLOOEHDVNHGWRDVVHVVWKHPD[LPXPLQWHQVLW\RIWKH
UHSRUWHG$(VDFFRUGLQJWRWKHIROORZLQJVFDOH
x 0LOGDZDUHQHVVRIVLJQRUV\PSWRPEXWHDVLO\WROHUDWHG
x 0RGHUDWHGLVFRPIRUWVXIILFLHQWWRFDXVHLQWHUIHUHQFHZLWKQRUPDODFWLYLWLHV
x 6HYHUHLQFDSDFLWDWLQJZLWKLQDELOLW\WRSHUIRUPQRUPDODFWLYLWLHV
$Q$(ZLWKPLVVLQJVHYHULW\JUDGHZLOOEHFRQVLGHUHGDV0RGHUDWH

5HODWLRQVKLSWR6WXG\7UHDWPHQW
7KHLQYHVWLJDWRUZLOODVVHVVFDXVDOUHODWLRQVKLSEHWZHHQ,QYHVWLJDWLRQDO3URGXFW,3ZKLFK
GRHVQRWLQFOXGH0HWIRUPLQDQGHDFK$(DQGDQVZHUµ\HV¶RUµQR¶WRWKHTXHVWLRQ³'R\RX
FRQVLGHUWKDWWKHUHLVDUHDVRQDEOHSRVVLELOLW\WKDWWKHHYHQWPD\KDYHEHHQFDXVHGE\WKH
LQYHVWLJDWLRQDOSURGXFW"´
$Q$(ZLWKPLVVLQJFDXVDOUHODWLRQVKLSZLOOEHFRQVLGHUHGUHODWHG

$(V/HDGLQJWR6WXG\:LWKGUDZDO7UHDWPHQW'LVFRQWLQXDWLRQ
$(VOHDGLQJWRVWXG\ZLWKGUDZDODQGSHUPDQHQWGLVFRQWLQXDWLRQRIVWXG\PHGLFDWLRQDUH$(
UHFRUGVZKHUH³6WXG\GUXJSHUPDQHQWO\GLVFRQWLQXHGGXHWRWKLVDGYHUVHHYHQW´LVFDSWXUHGRQ
³S$(´&5)SDJHDVWKHDFWLRQWDNHQZLWKVWXG\PHGLFDWLRQ6LQFHLQWKLVVWXG\HQGRI
WUHDWPHQWLVHTXLYDOHQWWRHQGRIVWXG\WKH\LQIRUPDWLRQFDQDOVREHH[WUDFWHGIURPTXHVWLRQ
³'RHVWKLV$(FDXVHSDWLHQW¶VZLWKGUDZDOIURPVWXG\´RQ³S$(´&5)
)RU$(VOHDGLQJWRGLVFRQWLQXDWLRQRIVWXG\PHGLFDWLRQVXPPDULHVRILQFLGHQFHUDWHV
IUHTXHQFLHVDQGSHUFHQWDJHVE\62&DQG37ZLOOEHSUHSDUHG

$(V/HDGLQJWR'RVH$GMXVWPHQWRU,QWHUUXSWLRQ
$(VOHDGLQJWRGRVHDGMXVWPHQWRULQWHUUXSWLRQDUH$(UHFRUGVZKHUH³6WXG\GUXJGRVDJH
DGMXVWHGWHPSRUDULO\LQWHUUXSWHG´LVFDSWXUHGRQ³S$(´&5)SDJHDVWKHDFWLRQWDNHQZLWK
VWXG\PHGLFDWLRQ
)RU$(VOHDGLQJWRGRVHDGMXVWPHQWRULQWHUUXSWLRQVXPPDULHVRILQFLGHQFHUDWHVIUHTXHQFLHV
DQGSHUFHQWDJHVE\62&DQG37ZLOOEHSUHSDUHG

6HULRXV$(V6$(V
6HULRXVDGYHUVHHYHQWV6$(VDUHWKRVHHYHQWVUHFRUGHGDV³6HULRXV´RQWKH³S$(´SDJHRI
WKH&5)$VXPPDU\RIVHULRXV$(VE\62&DQG37ZLOOEHSUHSDUHG
&ULWHULDIRU6$(VFDQEHIRXQGLQSURWRFRO6HFWLRQ

$(V/HDGLQJWR'HDWK
$(VOHDGLQJWRGHDWKDUHWKRVHHYHQWVZLWKDQRXWFRPHRI³IDWDO´RQWKH³S$(´&5)SDJH$
VXPPDU\RI$(VOHDGLQJWRGHDWKE\62&DQG37ZLOOEHSUHSDUHG


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\


+\SRJO\FHPLF(YHQWVDQG+\SRJO\FHPLF$(V
+\SRJO\FHPLF$(VDUHFDSWXUHGRQ³S$(´SDJHRIWKH&5)DQGLGHQWLILHGXVLQJTXHVWLRQ³,V
WKH$GYHUVH(YHQWDK\SRJO\FHPLFHYHQW"´+\SRJO\FHPLF$(VZLOOEHSUHVHQWHGE\62&DQG
37
6XEMHFWVUHSRUWLQJDWOHDVWRQHHSLVRGHRIDK\SRJO\FHPLFHYHQWZKLFKLVQRWQHFHVVDULO\DQ
$(DQGHYHQWIUHTXHQF\DUHFROOHFWHGRQ&5)SDJH³S',$5<<1´6XPPDU\RILQFLGHQFH
UDWHVHYHQWDPRXQWDQGSHUFHQWDJHVZLOOEHSUHSDUHGDQGFRUUHVSRQGLQJ&ORSSHU
3HDUVRQH[DFWFRQILGHQFHLQWHUYDOVIRUWKHSUREDELOLW\RIDVXEMHFWUHSRUWLQJDWOHDVWHYHQW
ZLOOEHUHSRUWHG$FRPSDULVRQEHWZHHQWKHWUHDWPHQWJURXSVZLOOEHSHUIRUPHGXVLQJWZR
VLGHG)LVKHU¶VH[DFWWHVWDQGUHVXOWLQJSYDOXHZLOOEHUHSRUWHG
ܪ଴ǣɎ୘ൌߨ௖ܸ݁ݎݏݑݏܪ஺ǣ ߨ்്ߨ஼
:KHUHɎ୘GHQRWHVWKHSUREDELOLW\RIUHSRUWLQJDK\SRJO\FHPLFHYHQWIRUVXEMHFWVUHFHLYHG
'DSDJOLIOR]LQ7UHDWPHQWXQGHULQYHVWLJDWLRQ7DQGߨ஼GHQRWHVWKHSUREDELOLW\RIUHSRUWLQJD
K\SRJO\FHPLFHYHQWIRUVXEMHFWVUHFHLYHG*OLPHSLULGH&RPSDUDWRU&
)UHTXHQFLHVRIK\SRJO\FHPLFHYHQWVUHSRUWHGE\HDFKVXEMHFWZLOOEHVXPPDUL]HGDQGOLVWHG
IRU6$)VHW

'HDWKV
,IDQ\SDWLHQWGLHVGXULQJWKHVWXG\UHOHYDQWLQIRUPDWLRQZLOOEHFDSWXUHGRQ&5)SDJH³S$(´
DVD6$(
,QFLGHQFHVDQGSHUFHQWDJHVRIGHDWKDQGZLOOEHVXPPDUL]HGDQGOLVWHG

/DERUDWRU\(YDOXDWLRQV
5HVXOWVIURPWKHFHQWUDOODERUDWRU\ZLOOEHLQFOXGHGLQWKHUHSRUWLQJIRUVHUXPFKHPLVWU\
KHPDWRORJ\DQGXULQDO\VLV$OLVWRIWHVWVWREHSHUIRUPHGLVLQFOXGHGLQ3URWRFROVHFWLRQ
7KHIROORZLQJVXPPDULHVZLOOEHSURYLGHGIRUODERUDWRU\GDWD
x $FWXDOYDOXHRIHDFKVFKHGXOHGYLVLWDQGFKDQJHIURPEDVHOLQHIRUHDFKSRVWEDVHOLQH
VFKHGXOHGPHDVXUHPHQWE\YLVLWIRUTXDQWLWDWLYHPHDVXUHPHQWVRQO\
x ,QFLGHQFHRIDEQRUPDOYDOXHVDFFRUGLQJWRQRUPDOUDQJHFULWHULD$EQRUPDOLWLHVZLOOEH
FODVVLILHGWR³/RZ´LIVPDOOHUWKDQWKHORZHUOLPLWZKLOH³+LJK´LIODUJHUWKDQWKH
XSSHUOLPLW
x 6KLIWIURPEDVHOLQHDFFRUGLQJWRDEQRUPDOLW\VWDWXV/RZ1RUPDODQG+LJKIRUHDFK
SRVWEDVHOLQHVFKHGXOHGPHDVXUHPHQW)RUXULQDO\VLVVKLIWEHWZHHQQRUPDODQG
DEQRUPDOZLOOEHSUHSDUHG
x /LVWLQJRIREVHUYHGUHVXOWVIRUDOOODERUDWRU\YDOXHVZLOOEHSURYLGHGZLWKDEQRUPDOLW\
VWDWXVIODJJHG


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

x $GGLWLRQDOO\&KDQJHIURPVFUHHQLQJYLVLWWRHDFKSRVWWUHDWPHQWWLPHSRLQWZLOOEH
UHSRUWHGIRU&%&HOHFWURO\WHVOLSLGSDUDPHWHUV

(&*(YDOXDWLRQV
(&*UHVXOWVZLOOEHFDSWXUHGRQ&5)SDJH³S(&*´DQGZLOOFRQWDLQRYHUDOODVVHVVPHQWEDVHG
RQ,QYHVWLJDWRU¶VMXGJPHQW

1RUPDO

$EQRUPDO1RW&OLQLFDOO\6LJQLILFDQW$1&6

$EQRUPDO&OLQLFDOO\6LJQLILFDQW$&6

)RUEDVHOLQHDQGHDFKSRVWEDVHOLQHPHDVXUHPHQWWKHQXPEHUVDQGSHUFHQWDJHVRISDWLHQWVLQ
HDFKFDWHJRU\DERYHZLOOEHVXPPDUL]HG
,QDGGLWLRQKHDUWUDWH35LQWHUYDO456LQWHUYDODQG47LQWHUYDOZLOOEHVXPPDUL]HGDQG
OLVWHGIRU6$)VHW

9LWDO6LJQV
9LWDOVLJQVUHVXOWVDUHUHFRUGHGRQ&5)SDJH³S3(´DQG³S3(´7KHIROORZLQJ9LWDO6LJQV
PHDVXUHPHQWVZLOOEHUHSRUWHGIRUWKLVVWXG\

6LWWLQJ6\VWROLF%ORRG3UHVVXUHPP+J

6LWWLQJ'LDVWROLF%ORRG3UHVVXUHPP+J

6LWWLQJ3XOVH5DWHESP

5HVSLUDWRU\5DWHSHUPLQ

:HLJKWNJ

%0,NJP

:DLVW&LUFXPIHUHQFHFP

%DVHOLQH+HLJKWFP

$ERYHYLWDOVLJQYDOXHVDQGFKDQJHIURPEDVHOLQHDSSOLFDEOHWRDOOSRVWEDVHOLQH
PHDVXUHPHQWVZLOOEHVXPPDUL]HGE\HDFKVFKHGXOHGWLPHSRLQWDQGSUHVHQWHGIRU6$)VHW
$GGLWLRQDOO\&KDQJHIURPVFUHHQLQJYLVLWWRHDFKSRVWWUHDWPHQWWLPHSRLQWZLOOEH
UHSRUWHGIRUYLWDOVLJQVSXOVH
$OOREVHUYHGYLWDOVLJQVZLOOEHOLVWHG

3K\VLFDO([DPLQDWLRQV
$SK\VLFDOH[DPLQDWLRQZLOOLQFOXGHDQDVVHVVPHQWRIWKHIROORZLQJJHQHUDODSSHDUDQFH
UHVSLUDWRU\FDUGLRYDVFXODUDEGRPHQKHDGDQGQHFNLQFOXGLQJKHDGHDUVH\HVQRVHDQG
WKURDW
)LQGLQJVLQHDFKERG\V\VWHPWHVWHGZLOOEHVXPPDUL]HGIRUDOOVFKHGXOHGYLVLWV7KH
H[DPLQDWLRQDWYLVLWZLOOEHFRQVLGHUHGDVEDVHOLQHDQGFKDQJHIURPEDVHOLQHZLOOEH
FDOFXODWHGIRUWKHIROORZLQJYLVLWV


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

$OOSK\VLFDOH[DPLQDWLRQUHVXOWVZLOOEHOLVWHGIRU6$)VHW

&+$1*(62)$1$/<6,6)52035272&2/
1RW$SSOLFDEOH

5()(5(1&(6
'/3URWRFRO9HUVLRQGDWHG-XQ
6WXG\DQQRWDWHG&5)9HUVLRQGDWHG-XO
$33(1',;/,672)352+,%,7('0(',&$7,216
WƌŽŚŝďŝƚĞĚDĞĚŝĐĂƚŝŽŶůĂƐƐ
'ĞŶĞƌŝĐdĞƌŵ
ŶƚŝŚǇƉĞƌŐůǇĐĂĞŵŝĐŵĞĚŝĐĂƚŝŽŶƐ
dŽůďƵƚĂŵŝĚĞ͕ŚůŽƌƉƌŽƉĂŵŝĚĞ͕dŽůĂǌĂŵŝĚĞ͕'ůŝĐůĂǌŝĚĞ͕'ůŝƉŝǌŝĚĞ͕
'ůǇďƵƌŝĚĞ͕EĂƚĞŐůŝŶŝĚĞ͕ZĞƉĂŐůŝŶŝĚĞ͕ŽƚŚĞƌŵĞƚĨŽƌŵŝŶĞǆĐĞƉƚ/W͕
ZŽƐŝŐůŝƚĂǌŽŶĞ͕WŝŽŐůŝƚĂǌŽŶĞ͕ĐĂƌďŽƐĞ͕sŽŐůŝďŽƐĞ͕sŝůĚĂŐůŝƉƚŝŶ͕
^ĂǆĂŐůŝƉƚŝŶ͕>ŝŶĂŐůŝƉƚŝŶ͕'ĞŵŝŐůŝƉƚŝŶ͕ůŽŐůŝƉƚŝŶ͕ǆĞŶĂƚŝĚĞ͕>ŝƌĂŐůƵƚŝĚĞ͕
ǆĞŶĂƚŝĚĞYt͕ĐĂƌďŽƐĞ͕sŽŐůŝďŽƐĞ͕ĐĂŶĂŐůŝĨůŽǌŝŶ͕ŝƉƌĂŐůŝĨůŽǌŝŶ͕
ĞǆĞŶĂƚŝĚĞ͕ůŝǆŝƐĞŶĂƚŝĚĞ͕ůŝƌĂŐůƵƚŝĚĞ͕ĂůĐŝŐůƵƚŝĚĞ
hŶƉĞƌŵŝƚƚĞĚŝŶƐƵůŝŶƵƐĞ
ĨŽƌƵƉƚŽϭϰĚĂǇƐƚŽƚĂůĚƵƌŝŶŐƚŚĞƐƚƵĚǇĂŶĚƵƉƚŽϳĐŽŶƚŝŶƵŽƵƐĚĂǇƐŝƐ
ƉĞƌŵŝƚƚĞĚ
^ǇƐƚĞŵŝĐĐŽƌƚŝĐŽƐƚĞƌŝŽĚƚŚĞƌĂƉǇ
,ǇĚƌŽĐŽƌƚŝƐŽŶĞ͕ŚǇĚƌŽĐŽƌƚŝƐŽŶĞĂĐĞƚĂƚĞ͕ĐŽƌƚŝƐŽŶĞĂĐĞƚĂƚĞ͕ƚŝǆŽĐŽƌƚŽů
ƉŝǀĂůĂƚĞ͕ƉƌĞĚŶŝƐŽůŽŶĞ͕ŵĞƚŚǇůƉƌĞĚŶŝƐŽůŽŶĞ͕ƉƌĞĚŶŝƐŽŶĞ͕
dƌŝĂŵĐŝŶŽůŽŶĞĂĐĞƚŽŶŝĚĞ͕ƚƌŝĂŵĐŝŶŽůŽŶĞĂůĐŽŚŽů͕ŵŽŵĞƚĂƐŽŶĞ͕
ĂŵĐŝŶŽŶŝĚĞ͕ďƵĚĞƐŽŶŝĚĞ͕ĚĞƐŽŶŝĚĞ͕ĨůƵŽĐŝŶŽŶŝĚĞ͕ĨůƵŽĐŝŶŽůŽŶĞ
ĂĐĞƚŽŶŝĚĞ͕ŚĂůĐŝŶŽŶŝĚĞ͕ĞƚĂŵĞƚŚĂƐŽŶĞ͕ďĞƚĂŵĞƚŚĂƐŽŶĞƐŽĚŝƵŵ
ƉŚŽƐƉŚĂƚĞ͕ĚĞǆĂŵĞƚŚĂƐŽŶĞ͕ĚĞǆĂŵĞƚŚĂƐŽŶĞƐŽĚŝƵŵƉŚŽƐƉŚĂƚĞ͕
ĨůƵŽĐŽƌƚŽůŽŶĞ͕,ǇĚƌŽĐŽƌƚŝƐŽŶĞͲϭϳͲǀĂůĞƌĂƚĞ͕ŚĂůŽŵĞƚĂƐŽŶĞ͕
ĂůĐůŽŵĞƚĂƐŽŶĞĚŝƉƌŽƉŝŽŶĂƚĞ͕ďĞƚĂŵĞƚŚĂƐŽŶĞǀĂůĞƌĂƚĞ͕ďĞƚĂŵĞƚŚĂƐŽŶĞ
ĚŝƉƌŽƉŝŽŶĂƚĞ͕ƉƌĞĚŶŝĐĂƌďĂƚĞ͕ĐůŽďĞƚĂƐŽŶĞͲϭϳͲďƵƚǇƌĂƚĞ͕ĐůŽďĞƚĂƐŽůͲϭϳͲ
ƉƌŽƉŝŽŶĂƚĞ͕ĨůƵŽĐŽƌƚŽůŽŶĞĐĂƉƌŽĂƚĞ͕ĨůƵŽĐŽƌƚŽůŽŶĞƉŝǀĂůĂƚĞ͕
ĨůƵƉƌĞĚŶŝĚĞŶĞĂĐĞƚĂƚĞ͕,ǇĚƌŽĐŽƌƚŝƐŽŶĞͲϭϳͲďƵƚǇƌĂƚĞ͕ŚǇĚƌŽĐŽƌƚŝƐŽŶĞͲ
ϭϳͲĂĐĞƉŽŶĂƚĞ͕ŚǇĚƌŽĐŽƌƚŝƐŽŶĞͲϭϳͲďƵƚĞƉƌĂƚĞ͕ĐŝĐůĞƐŽŶŝĚĞ͕
ƉƌĞĚŶŝĐĂƌďĂƚĞ͘
DĞĚŝĐĂƚŝŽŶƐƉŽƚĞŶƚŝĂůůǇŝŶĨůƵĞŶĐĞŽŶďŽŶĞ
ŵĞƚĂďŽůŝƐŵ
ŶĂƐƚƌĂǌŽůĞ͕ĞǆĞŵĞƐƚĂŶĞ͕ůĞƚƌŽǌŽůĞ͕ůĞƵƉƌŽƌĞůŝŶĂĐĞƚĂƚĞ͕ŐŽƐĞƌĞůŝŶ͕
ŚǇĚƌŽĐŽƌƚŝƐŽŶĞ͕ƉƌĞĚŶŝƐŽůŽŶĞ
dĂŵŽǆŝĨĞŶ;ƉƌĞŵĞŶŽƉĂƵƐĂůƵƐĞͿ͕ƉŝŽŐůŝƚĂǌŽŶĞĂŶĚƌŽƐŝŐůŝƚĂǌŽŶĞ
ŵĂůĞĂƚĞ͕,ĞƉĂƌŝŶ͕ǁĂƌĨĂƌŝŶ͕ĐǇĐůŽƐƉŽƌŝŶĞ͕ŐůƵĐŽĐŽƌƚŝĐŽŝĚƐ͕
ŵĞĚƌŽǆǇƉƌŽŐĞƐƚĞƌŽŶĞĂĐĞƚĂƚĞ͕ƚŚǇƌŽŝĚŚŽƌŵŽŶĞ͕
EŽƚĞ͗ƐƐƵŵĞĚ͕ƚŚĞƐĞŵĞĚŝĐĂƚŝŽŶƐǁŝůůŚĂǀĞŵŝŶŽƌŝŵƉĂĐƚĂŶĚǁŝůůŶŽƚ
ŝŵƉĂĐƚWW^ƉŽƉƵůĂƚŝŽŶ͘
ŶƚŝͲŽďĞƐŝƚǇŵĞĚŝĐĂƚŝŽŶ
ŶǇĂŶƚŝͲŽďĞƐŝƚǇŵĞĚŝĐĂŝƚŽŶ
,ŽƌŵŽŶĞƌĞƉůĂĐĞŵĞŶƚƚŚĞƌĂƉǇ
EŽƚŝŶĐůƵĚŝŶŐůŽĐĂůƚƌĞĂƚŵĞŶƚ
^ŝďƵƚƌĂŵŝŶĞ
^ŝďƵƚƌĂŵŝŶĞ
WŚĞŶƚĞƌŵŝŶĞ
WŚĞŶƚĞƌŵŝŶĞ


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

KƌůŝƐƚĂƚ
KƌůŝƐƚĂƚ
ZŝŵŽŶĂďĂŶƚ
ZŝŵŽŶĂďĂŶƚ
ĞŶǌƉŚĞƚĂŵŝŶĞ
ĞŶǌƉŚĞƚĂŵŝŶĞ
ŝĞƚŚǇůƉƌŽƉŝŽŶ
ŝĞƚŚǇůƉƌŽƉŝŽŶ
DĞƚŚĂŵƉŚĞƚĂŵŝŶĞ
DĞƚŚĂŵƉŚĞƚĂŵŝŶĞ
WŚĞŶĚŝŵĞƚƌĂǌŝŶĞ
WŚĞŶĚŝŵĞƚƌĂǌŝŶĞ
$33(1',;352*5$00,1*&219(17,216)252873876
ĂƚĞƐΘdŝŵĞƐ
ĞƉĞŶĚŝŶŐŽŶĚĂƚĂĂǀĂŝůĂďůĞ͕ĚĂƚĞƐĂŶĚƚŝŵĞƐǁŝůůƚĂŬĞƚŚĞĨŽƌŵDDDzzzzĂŶĚ,,͗DD͗^^͘

^ƉĞůůŝŶŐ&ŽƌŵĂƚ
ŶŐůŝƐŚh^

WƌĞƐĞŶƚĂƚŝŽŶŽĨdƌĞĂƚŵĞŶƚ'ƌŽƵƉƐ
ůůƐƵŵŵĂƌŝĞƐǁŝůůďĞƉƌĞƐĞŶƚĞĚďǇĂƐƐŝŐŶĞĚĚŽƐĞůĞǀĞů͘ŽƐĞĞǆƉĂŶƐŝŽŶƉŚĂƐĞƐƵďũĞĐƚƐǁŝůůďĞŝŶĐůƵĚĞĚŝŶ
ƚŚĞŝƌĚŽƐĞůĞǀĞůŐƌŽƵƉ͕ĂŶĚƉƌĞƐĞŶƚĞĚƚŽŐĞƚŚĞƌǁŝƚŚĚŽƐĞĞƐĐĂůĂƚŝŽŶƐƵďũĞĐƚƐƌĞĐĞŝǀŝŶŐƚŚĞƐĂŵĞĚŽƐĞůĞǀĞů͘
dƌĞĂƚŵĞŶƚ'ƌŽƵƉ
&ŽƌdĂďůĞƐ͕>ŝƐƚŝŶŐƐĂŶĚ'ƌĂƉŚƐ
ĂƉĂŐůŝĨůŽǌŝŶϭϬŵŐY
dƌƚ
'ůŝŵĞƉŝƌŝĚĞϭƚŽϮŵŐY
dƌƚ'
^ĐƌĞĞŶĨĂŝůƵƌĞƐ;ŝŶůŝƐƚŝŶŐƐŽŶůǇͿ
^&
hŶƚƌĞĂƚĞĚĞůŝŐŝďůĞƐƵďũĞĐƚƐ;ŝŶůŝƐƚŝŶŐƐŽŶůǇͿ
EKddZd

WƌĞƐĞŶƚŝŶŐKƌĚĞƌ
ůůůŝƐƚŝŶŐƐǁŝůůďĞŽƌĚĞƌĞĚďǇƚŚĞĨŽůůŽǁŝŶŐ;ƵŶůĞƐƐŽƚŚĞƌǁŝƐĞŝŶĚŝĐĂƚĞĚŝŶƚŚĞƚĞŵƉůĂƚĞͿ͗
x
ĐĞŶƚĞƌͲƐƵďũĞĐƚ/͕
x
dƌĞĂƚŵĞŶƚŐƌŽƵƉ͕ŝŶƚŚĞŽƌĚĞƌĂƐĂďŽǀĞƚĂďůĞ͕
x
ĚĂƚĞ;ǁŚĞƌĞĂƉƉůŝĐĂďůĞͿ


6WDWLVWLFDO$QDO\VLV3ODQ
6WXG\&RGH)HEUXDU\
(GLWLRQ1XPEHU9
'DWH)HEUXDU\

ůůƚĂďůĞƐĐŽŶƚĂŝŶŝŶŐĐŽĚĞĚƚĞƌŵƐ;D͕D,͕͕ĞƚĐͿ͕ĐŽĚĞĚƌĞĐŽƌĚƐǁŝůůďĞƐŽƌƚĞĚŝŶĂůƉŚĂďĞƚŝĐŽƌĚĞƌ͘
